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A B S T R A C T
Background
Current guidelines recommend oral anticoagulation therapy for patients with atrial fibrillation (AF) with one or more risk factors for
stroke; however, anticoagulation control (time in therapeutic range (TTR)) with vitamin K antagonists (VKAs) is dependent on many
factors. Educational and behavioural interventions may impact patients’ ability to maintain their international normalised ratio (INR)
control. This is an updated version of the original review first published in 2013.
Objectives
To evaluate the effects of educational and behavioural interventions for oral anticoagulation therapy (OAT) on TTR in patients with
AF.
Search methods
We updated searches from the previous review by searching the Cochrane Central Register of Controlled Trials (CENTRAL) and the
Database of Abstracts of Reviews of Effects (DARE) in The Cochrane Library (January 2016, Issue 1), MEDLINE Ovid (1949 to
February week 1 2016), EMBASEClassic + EMBASEOvid (1980 toWeek 7 2016), PsycINFOOvid (1806 toWeek 1 February 2016)
and CINAHL Plus with Full Text EBSCO (1937 to 16/02/2016). We applied no language restrictions.
Selection criteria
We included randomised controlled trials evaluating the effect of any educational and behavioural intervention compared with usual
care, no intervention, or intervention in combination with other self-management techniques among adults with AF who were eligible
for, or currently receiving, OAT.
Data collection and analysis
Two of the review authors independently selected studies and extracted data. Risk of bias was assessed using the Cochrane ’Risk of
bias’ tool. We included outcome data on TTR, decision conflict (patient’s uncertainty in making health-related decisions), percentage
of INRs in the therapeutic range, major bleeding, stroke and thromboembolic events, patient knowledge, patient satisfaction, quality
of life (QoL), beliefs about medication, illness perceptions, and anxiety and depression. We pooled data for three outcomes - TTR,
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anxiety and depression, and decision conflict - and reported mean differences (MD). Where insufficient data were present to conduct
a meta-analysis, we reported effect sizes and confidence intervals (CI) from the included studies. We evaluated the quality of evidence
using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.
Main results
Eleven trials with a total of 2246 AF patients (ranging from 14 to 712 by study) were included within the review. Studies included
education, decision aids, and self-monitoring plus education interventions. The effect of self-monitoring plus education on TTR was
uncertain compared with usual care (MD 6.31, 95% CI -5.63 to 18.25, I2 = 0%, 2 trials, 69 participants, very low-quality evidence).
We found small but positive effects of education on anxiety (MD -0.62, 95% CI -1.21 to -0.04, I2 = 0%, 2 trials, 587 participants,
low-quality evidence) and depression (MD -0.74, 95% CI -1.34 to -0.14, I2 = 0%, 2 trials, 587 participants, low-quality evidence)
compared with usual care. The effect of decision aids on decision conflict favoured usual care (MD -0.1, 95% CI -0.17 to -0.02, I2 =
0%, 2 trials, 721 participants, low-quality evidence).
Authors’ conclusions
This review demonstrates that there is insufficient evidence to draw definitive conclusions regarding the impact of educational or
behavioural interventions on TTR in AF patients receivingOAT. Thus, more trials are needed to examine the impact of interventions on
anticoagulation control in AF patients and the mechanisms by which they are successful. It is also important to explore the psychological
implications for patients suffering from this long-term chronic condition.
P L A I N L A N G U A G E S U M M A R Y
Educational and behavioural interventions to increase the time in the therapeutic range for patients with atrial fibrillation on
anticoagulant therapy
Review question
We reviewed the evidence about the effects of educational and behavioural interventions in patients with atrial fibrillation who are
taking oral anticoagulant medication.
Background
Atrial fibrillation is characterised by an irregular heartbeat and places people at greater risk of forming blood clots and having a stroke.
To reduce stroke risk, medication that ’thins the blood’ is used, known as oral anticoagulants. For patients taking warfarin, regular
patient monitoring assesses the time it takes for blood to clot, known as the international normalised ratio (INR), to ensure that the
target therapeutic range of 2.0 to 3.0 is maintained. This is often difficult to achieve due to the many factors that can affect INR control
such as alcohol intake, other medications, and food.
Educational and behavioural interventions may play an important role in improving the ability of people with atrial fibrillation to
maintain their INR control, by increasing patient knowledge and understanding.
Study characteristics
This is an update of the original review first published in 2013. We searched scientific databases in February 2016 and found 11
randomised clinical trials including 2246 adults with atrial fibrillation who were taking oral anticoagulant medication. The trials we
found compared education, decision aids, and self-monitoring plus education to usual care, over any length of time.
Key results
Few studies had comparable groups and data. There was uncertainty about the effect of self-monitoring plus education on the percentage
of time the INRwaswithin the therapeutic range because the proportion or time in the therapeutic range was similar between individuals
who received self-monitoring plus education and those who did not. There were small and positive effects on anxiety and depression
in individuals who received education compared to those who received usual care. There were small and negative effects on decision
conflict in individuals who received decision aids compared to those who received usual care.
Quality of the evidence
The evidence should be interpreted with caution as the quality of the evidence ranged from very low to low across different outcomes
because of the limitations of individual studies. It is likely that further high-quality trials may affect these reported results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Education, self-monitoring plus education, and decision aids compared to usual care for oral anticoagulant therapy in patients with atrial fibrillation
Patient or population: oral ant icoagulant therapy in pat ients with atrial f ibrillat ion
Setting: hospital, ant icoagulat ion clinic, general physician pract ice, or research clinic
Intervention: educat ion, self -monitoring plus educat ion, or decision aid as noted
Comparison: usual care
Outcomes Intervention Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Risk with usual care Risk with Interven-
tion
Percentage of t ime
within the therapeu-
t ic range
Self -monitoring plus
educat ion
The mean time
in therapeut ic INR
range was 0
MD 6.31 higher
(5.63 lower to 18.25
higher)
Not est imable 69
(2 RCTs)
⊕©©©
VERY LOW 123
Indirect compari-
son as self -mon-
itoring was com-
pared to placebo
and self -manage-
ment was compared
to placebo, but self -
monitoring and self -
management were
not direct ly com-
pared
HADS anxiety Educat ion The mean HADS
anxiety was 0
MD 0.62 lower
(1.21 lower to 0.04
lower)
Not est imable 587
(2 RCTs)
⊕⊕©©
LOW 23
HADS depression Educat ion The mean HADS de-
pression was 0
MD 0.74 lower
(1.34 lower to 0.14
lower)
Not est imable 587
(2 RCTs)
⊕⊕©©
LOW 23
Decision conf lict Decision aid The mean decision
conf lict was 0
MD 0.1 lower
(0.17 lower to 0.02
lower)
Not est imable 721
(2 RCTs)
⊕⊕©©
LOW 24
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; INR: internat ional normalised rat io; M D: mean dif ference; RCT: randomised controlled trial; HADS: Hospital Anxiety and Depression Scale
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded due to study lim itat ions including small study bias (all pat ients had to be eligible for self -management of oral
ant icoagulat ion and therefore may not be representat ive of all AF pat ients requiring oral ant icoagulat ion)
2Downgraded due to attrit ion bias
3Downgraded due to select ion bias
4Downgraded due to performance bias
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B A C K G R O U N D
Description of the condition
Atrial fibrillation (AF) is the most common arrhythmia in clin-
ical practice (Kirchhof 2016). The lifetime risk of developing
AF is approximately one in four among people aged 40 years or
older (Lloyd-Jones 2004; McManus 2012). The incidence and
prevalence of AF is rising (Chugh 2014; Colilla 2013; Krijthe
2013).The prevalence of AF dramatically increases with age, rising
from 0.5% at 40 to 50 years of age to 5% to 15% at 80 years
(Chugh 2014; Colilla 2013; Heeringa 2006; Krijthe 2013; Lane
2017; Lloyd-Jones 2004; Miyasaka 2006), with the prevalence
being slightly higher in men than in women (Lloyd-Jones 2004;
McManus 2012). One US population-based study (N = 4618)
found the age- and sex-adjusted incidence of AF per 1000 person-
years was 3.04 (95% CI 2.78 to 3.31) in 1980, increasing to 3.68
(95% CI 3.42 to 3.95) in 2000, amounting to a relative increase
of 12.6% (Miyasaka 2006). Similar findings in the European Rot-
terdam Study (N = 6806) found that the overall prevalence of
AF was 5.5% to 6.0% in men and 5.1% in women (Heeringa
2006). Recent analyses of the Clinical Practice Research Datalink
in the UK demonstrate a constant yearly rise in the prevalence of
AF nationally, increasing from 700,000 patients in 2010 to a pro-
jected prevalence of between 1.3 million and 1.8 million patients
by 2060 (Lane 2017). AF is associated with a five-fold greater risk
of stroke and thromboembolism (Wolf 1991), and the incidence
of stroke attributable to AF also increases with age (Lip 2006).
AF-related stroke is likely to be more severe than non-AF related
stroke (Sheikh 2015; Wolf 1991). When including hospital ad-
missions, treatment costs, and long-term nursing home care, AF
accounts for 1% of the total UK healthcare expenditure (Sheikh
2015). Given the increasing incidence and prevalence of AF, these
figures are likely to rise.
Patients with an increased risk of stroke (as determined by stroke
risk stratification models) should receive long-term oral anti-
coagulant therapy (OAT): either vitamin K antagonists (VKA)
such as warfarin, or non-vitamin K antagonist oral anticoagulants
(NOAC) such as apixaban, dabigatran, edoxaban, or rivaroxaban,
unless contraindicated. In a meta-analysis, dose-adjusted OAT, re-
sulting in international normalized ratio (INR) values in the range
of 2.0 to 3.0, significantly reduced the risk of ischaemic stroke or
thromboembolism in patients with non-valvular AF by 39% (95%
CI 22% to 52%) and 64% (95% CI 41% to 62%), respectively,
compared with either aspirin or placebo (Hart 2007).Whilst OAT
dramatically reduces stroke risk, the therapeutic range of the INR
is narrow and must be maintained. This can be problematic, with
INRs greater than 3.0 increasing the risk of major and minor
bleeding and INRs less than 2.0 increasing the risk of thromboem-
bolism (Lip 2006). Regular INR monitoring is essential and pa-
tients need to carefully adhere to dietary and lifestyle restrictions
(Ansell 2004). A retrospective analysis of OAT in the UK demon-
strated that only patients with the greatest INR control increased
their time to stroke occurrence, with only patients spending over
71% of their time in the target therapeutic range (TTR) benefit-
ing (Morgan 2009). In practice, 51% of patients at high risk of
stroke (CHADS2 score 2 or more) remained outside of the target
therapeutic range for at least 50% of the time (Morgan 2009).
Further, a post hoc analysis of patients enrolled in the Atrial Fib-
rillation Clopidogrel Trial With Irbesartan for Prevention of Vas-
cular Events (ACTIVE), which randomised AF patients with one
additional stroke risk factor to receive clopidogrel 75 mg/day plus
aspirin (75 to 100 mg/day recommended dose) or OAT, found
that patients with a TTR less than 58% gained no benefit from
OAT. The INR must be within the therapeutic range for at least
58% of the time to confer benefit in terms of stroke risk reduction
(Connolly 2008). Thus, maintenance of INR is a major concern
for both AF patients and healthcare professionals. Furthermore,
whilst interventions targeting this patient group ultimately aim
to reduce the risk of stroke, patients’ TTR is a good short-term
indicator of whether the patients will experience adverse events in
the long-term, thus presenting a useful trial endpoint.
The inherent difficulties associated with VKAs (narrow therapeu-
tic range; drug, alcohol, and food interactions; regular blood tests)
have led to the development of NOACs, which have sought to
overcome these problems by providing an efficacious and safe al-
ternative treatment that does not require regular monitoring. Sev-
eral NOACs are now available (apixaban, dabigatran, edoxaban,
and rivaroxaban) and all are non-inferior to warfarin for the pre-
vention of stroke and systemic embolism, with similar (for dabiga-
tran 150 mg twice daily and rivaroxaban) or better safety profiles
(dabigatran 110 mg twice daily, apixaban, and edoxaban) and a
significant reduction in intracranial haemorrhage for all NOACs
(Connolly 2009;Giugliano 2013;Granger 2011; Patel 2011). The
use of NOACs may shift the focus of interventions for this patient
group, but VKAs (i.e. warfarin) are still widely used in AF patients
and it is important to investigate ways in which we can improve
the outcomes of patients still taking VKAs and whether the prin-
ciples used for interventions with this group are also relevant for
those taking NOACs.
Given that AF is a chronic condition that places patients at in-
creased risk of mortality and morbidity - particularly from stroke
- and often requires life-long treatment, including chronic OAT,
the educational materials and the support given to patients when
they are first prescribed OAT are crucial for the maintenance of
their treatment regimens.
Description of the intervention
Attempts to support behaviour change can take numerous forms.
At the individual level they almost always fall into the category of
’education or communication’ andmay use one ormore behaviour
change techniques (Michie 2011; NICE 2007). While some in-
terventions are designed to target regimen simplicity or access to
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testing, education is vital to enable patient uptake and adherence
(to medication, treatment regimen, and lifestyle changes). Indeed,
patient education for OAT has attempted to influence behaviour
by improving knowledge, attitudes, and practices that are neces-
sary to improve health outcomes (Wofford 2008). Yet very few
studies define their intervention components in a standardised
way, despite novel guidelines that give explicit guidance on how
to do so (Michie 2011).
In recent years increased attention has been paid to the classifi-
cation of behaviour change techniques to aid the development
and design of interventions. The behaviour change taxonomy de-
scribes 93 distinct techniques that can be applied to understanding
a range of health-related behaviours. The taxonomy was validated
using obesity and tobacco use as examples, but can be applied to
a range of health behaviours including adherence. Defining an in-
tervention using these techniques at the development stage could
influence the success of the intervention (Michie 2009; Michie
2013).
Techniques used in delivering patient education cover a wide spec-
trum, including the use of booklets and videos asmedia to transmit
information either alone or in addition to self-management inter-
ventions (such as INR self-monitoring) and interventions that use
decision aids (Khan 2004; Man-Son-Hing 1999). Patient knowl-
edge surrounding OAT varies with age, with elderly patients (>
75 years) demonstrating poorer knowledge (Tang 2003). In one
study, less than half of participants were able to name even one
specific benefit, risk, or lifestyle change associated with warfarin
(Coehlo-Dantas 2004). In several cases, spouses were more knowl-
edgeable than the patients and appeared to play a vital role in
monitoring the individuals’ treatment regimens (Coehlo-Dantas
2004). Therefore, educational interventions for this patient group
may prove to be particularly beneficial.
Other interventions focus on behavioural and practical aspects
of lifestyle change and treatment. Behavioural interventions aim
to modify patients’ behaviour towards treatment and symptoms
(NICE 2007). Interventions that use these principles to promote
change include cognitive behavioural therapy (CBT), motiva-
tional interviewing, and heart rate variability biofeedback. CBT
is a goal-oriented, systematic procedure which aims to solve prob-
lems concerning dysfunctional emotions, behaviours, and cogni-
tions and to promote positive attitude, self efficacy, and planning.
However, with any complex intervention it is difficult to deter-
mine which component has influenced the behavioural outcome,
as researchers often do not define the active components of the
intervention and interventions vary in duration and levels of sup-
port. Clearly it is important for trials to be explicit about the con-
tent and delivery of their interventions and to choose appropriate
evaluative tools in order to examine how and why their interven-
tions are successful, by using an applied behaviour change model
(Kok 2016; Michie 2011).
How the intervention might work
Interventions for patients with AF who receive OAT should ulti-
mately aim to improve clinical outcomes, primarily reducing the
prevalence of stroke and mortality. However, in the short-term
we can aim to increase patients’ TTR by focusing on factors that
affect treatment adherence. Many factors can affect INR control,
such as drug-drug interactions and variable dietary vitamin K in-
take (Holbrook 2005), but with adequate knowledge surround-
ing treatment and lifestyle factors, interventions should aim to
encourage behaviour change.
It has been suggested that several factors influence adherence
(Horne 2013; Lane 2015; Thrall 2004), and these factors are ei-
ther intentional or unintentional. Intentional non-adherence can
occur when patients make a decision not to take their treatment
as a result of their personal motivations or beliefs, or both (Horne
2013). Unintentional non-adherence refers to an individual’s skills
or ability to take his or hermedications (for example problemswith
remembering to take tablets). Poor INR control could result from
both unintentional and intentional non-adherence (Horne 2013).
Where patients’ knowledge of their condition and their OAT is
limited, this may impact on their practical ability to manage treat-
ment (unintentional) and their perceptions surrounding treatment
necessity (intentional). Indeed several studies have demonstrated
that patients have poor knowledge of AF and its treatment (Lane
2006; Lip 2002; Nadar 2003; Tang 2003).
There is evidence that patient knowledge correlates significantly
with TTR (Tang 2003), with more knowledgeable patients hav-
ing a better TTR. Thus if education can demonstrate an improve-
ment in TTR, it could have important clinical benefits (that is the
reduction of adverse events such as stroke and major bleeding).
Decision aids are informative interventions designed to help peo-
ple make specific choices surrounding their medications, and they
may also increase patient knowledge. These interventions aim to
reduce decision conflict, which refers to the patient’s uncertainty
in making health-related decisions and the factors relating to that
uncertainty, which may subsequently impact on treatment uptake
and adherence.
Intentional non-adherence may be more difficult to target and
interventions need to focus on inaccurate perceptions of medi-
cations. The common sense model (Horne 1999) suggests that
patients hold beliefs about the necessity of their prescribed med-
ication (Specific-Necessity) and concerns about prescribed med-
ication based on beliefs about the danger of dependence and
long-term toxicity as well as the disruptive effects of the medica-
tion (Specific-Concerns). The model also describes general beliefs
about medication, assessing beliefs that medicines are addictive
and harmful (General-Harm) and that medicines are over-pre-
scribed by doctors (General-Overuse). These beliefs, and the way
in which patients balance their concern about medications, have
been widely used in predicting medication adherence in a vari-
ety of chronic conditions including rheumatoid arthritis (Neame
2005), asthma (Jessop 2003), type II diabetes (Farmer 2006), and
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depression (Aikens 2005).
A comparison of beliefs about medications between adherent,
unintentional non-adherent, and intentionally non-adherent pa-
tients found significant differences in medication-related beliefs
in patients with a range of chronic illnesses after being newly pre-
scribedmedication for the last 10 days (Clifford 2008). Compared
with adherers, intentional non-adherers had significantly lower
scores on the necessity sub-scale of the Beliefs about Medication
Questionnaire (P = 0.012), higher scores on the concerns sub scale
(P = 0.008), and lower scores on the necessity-concerns differen-
tial (P = 0.001). There were no significant differences between ad-
herers and unintentional non-adherers (Clifford 2008). Evidently,
whilst unintentional non-adherers may benefit frommemory aids
(that is reminders, tablet dosettes), intentional non-adherers may
need to address both their perceptions of their medication and
misinformation, whichmay be achieved by increasing patient edu-
cation surrounding their treatment. Intentional non-adherers ap-
pear to doubt their personal need for their medication and have
concerns about taking it when compared to adherers.
More recent models critique the categories of ‘intentional’ and
‘unintentional’, as there is overlap between the categories. For ex-
ample, whilst forgetting is unintentional it may be influenced by
intentional or motivational factors (McHorney 2011). The capa-
bility, opportunity and motivation (COM-B) model of behaviour
was developed in order to choose interventions that are most likely
to be effective and specific for the individual behaviour (Jackson
2014). This model hypothesises that the interaction between an
individual’s capability, opportunity and motivation (COM) cause
the performance of behaviour (B). Thus the model provides ex-
planations for why patients do not adhere to treatment regimens.
Patient’s capability includes their psychological and physical ca-
pacity to engage in necessary thought processes including disease
comprehension, cognitive functioning (e.g. memory capacity) and
executive function (e.g. capacity to plan). A complex medication
regimen, such as with a VKA (i.e. warfarin), might be beyond the
psychological planning capabilities of some patients. Motivation is
defined as brain processes that energise and direct behaviour such
as the perception of illness, beliefs about treatment, self-efficacy
and outcome expectancies. Some evidence suggests that individ-
uals with complex regimens for several conditions choose to take
the medication that offers the most symptom relief, or is treating
the most feared condition (Nunes 2009). Opportunity is defined
as the physical opportunity provided by the environment includ-
ing cost, access, physical characteristics of the medicine, regimen
complexity, social support and the relationship with the health-
care provider (HCP). For VKAs this may include the barriers to
regular INR testing, and the social support required to attend ap-
pointments and make and maintain lifestyle changes. This model
provides a more precise method of defining the causes of non-
adherence, going beyond the dichotomies of intentional and un-
intentional, and thus may prove to be a useful model when devel-
oping interventions with this patient group.
Research suggests that interventions with the greatest likelihood
of success are theoretically underpinned, and precisely describe the
behavioural change techniques employed to address the needs of
target patient group (Michie 2009; Michie 2013).
Why it is important to do this review
AF is a condition that is increasing in prevalence (Chugh 2014;
Lane 2017; Miyasaka 2006) and requires treatment with OAT to
reduce associated stroke risk. However, patients on VKAs need to
maintain a narrow therapeutic INR range, which may be difficult
to achieve in practice (Morgan 2009). Patients need sufficient in-
formation tomake informed choices and actively participate in the
management of their own treatment (Lane 2015; Thrall 2004).
Patient education aims to influence patient behaviour and improve
knowledge, attitudes, and practices that are necessary to improve
health outcomes (Wofford 2008), but the efficacy of patient in-
terventions designed to improve AF patient adherence to OAT
is not clear. By increasing patient knowledge and understanding
surrounding AF and OATwe may reduce the prevalence of inten-
tional and unintentional non-adherence, and increase patient mo-
tivation to adhere, in addition to providing patients with the tools
to improve their planning and capability to incorporate the regi-
men requiredwithVKA therapy into their lifestyle (Jackson 2014),
which may subsequently increase TTR. TTR is important and has
been shown to be a predictor of thromboembolic or haemorrhagic
complications, although it is a surrogate for the hard endpoints
such as reductions in mortality and stroke that OAT is aimed at
achieving. Many factors influence TTR, including adherence to
medication and lifestyle factors (e.g., alcohol intake, diet and other
medications), however, TTR does give an indication as to whether
patients are adhering to the regimen required for VKA therapy,
which should translate into a reduction in stroke and major bleed-
ing events. We updated our previous review (Clarkesmith 2013)
to evaluate the value of educational and behavioural interventions
for patients with AF who were currently prescribed VKA (mainly
warfarin), including the impact on TTR and secondary outcomes
such as decision conflict, patient knowledge, and quality of life.
O B J E C T I V E S
To evaluate the effects on TTR of educational and behavioural
interventions for OAT in patients with AF.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We included randomised controlled trials (RCTs) of educational
or behavioural interventions with any length of follow-up and in
any language.
Types of participants
Adults (aged 18 years or older) with AF, categorised according to
the European Society of Cardiology (ESC) guidelines (Kirchhof
2016), including:
• newly diagnosed AF;
• paroxysmal AF, defined as episodes that usually terminate
spontaneously (usually in less than 48 hours), but may last for up
to seven days;
• persistent AF, characterised by an episode lasting more than
seven days or requiring termination via cardioversion;
• long-standing persistent AF, where AF has been present for
> one year (i.e. permanent AF) but where a rhythm control
strategy is adopted;
• permanent AF, where AF has been continuous for more
than one year and accepted as the ’normal’ heart rhythm by the
patient and the physician (hence no rhythm control adopted).
AF was diagnosed and documented by electrocardiogram (12-lead
or Holter monitoring). Patients that were eligible for, or currently
receiving, OAT were considered for inclusion in this review. We
also included studies which included AF patients with other med-
ical conditions in this review. The studies were RCTs comparing
at least one intervention with a control group, and including pa-
tients with AF as either the study population or a specified sub-
group. We only included studies where patients were grouped per
indication, that is for patients taking oral anticoagulants for AF,
deep vein thrombosis (DVT) or pulmonary embolism (PE), valve
replacements, etc, we only included AF patient data within the
analysis.
Types of interventions
We considered all types of educational and behavioural interven-
tions given to AF patients who were taking OAT for this system-
atic review. Educational interventions included those that deliv-
ered patient information, such as:
• educational booklets;
• videos as media to transmit additional information;
• self-management interventions (such as INR self-
monitoring) that also educated patients;
• decision aids;
• talking interventions.
Behavioural interventions included techniques that attempted to
modify patients’ behaviour towards treatment and symptoms, such
as:
• cognitive behavioural therapy (CBT);
• self-monitoring or management interventions that include
significant educational components;
• motivational interviewing;
• heart rate variability biofeedback.
Interventions could target adults on the individual level or as a
group. The intervention may have taken place in the emergency
department, a hospital, the home, or in the community and could
have been delivered by a nurse, pharmacist, educator, health or
medical practitioner, or a multidisciplinary team associated with
the hospital or referred to by the hospital. The intervention could
have been undertaken at any time point from diagnosis of AF or
initiation of OAT (that is not only newly diagnosed AF patients or
those newly referred for anticoagulant therapy). We only consid-
ered trials where the comparison groups were usual care, no inter-
vention, or the intervention in combination with other self-man-
agement techniques. We defined usual care as standard anticoagu-
lation clinic practice, where patients attended routine INR checks
(defined as usual care by the author). We included any length
of follow-up. We have endeavoured to ensure that our review is
clearly distinct from the Garcia-Alamino 2010 review, which ex-
clusively evaluated the effects of self-monitoring or self-manage-
ment of OAT compared to standard monitoring. In particular,
we have only included self-monitoring interventions where they
include a clear and distinct educational component (in addition
to training on the use of the self-monitoring device); this should
include topics in addition to self-testing, such as risk information,
lifestyle changes, and information pertaining to their condition.
Types of outcome measures
Primary outcomes
The primary outcome measure was TTR, as defined by Rosendaal
1993 (INR 2.0 to 3.0).
Secondary outcomes
The secondary outcomes were:
• major bleeding (defined as bleeds that result in death, are
life threatening, cause chronic sequelae, or consume major
healthcare resources) and minor bleeding (Schulman 2004);
• stroke and thromboembolic events;
• increased knowledge with regard to AF and anticoagulation
therapy;
• patient satisfaction;
• acceptability of the anticoagulant therapy;
• quality of life; psychological well-being (anxiety and
depression);
• changes in perception towards AF and INR control;
• changes in the patients’ illness beliefs and illness
representations;
8Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• self-reported adherence to treatment and a change in the
patients’ beliefs about medications;
• economic costs of the intervention (cost-effectiveness);
• decision conflict*.
*We included decision conflict as a secondary outcome in the
final analysis. Whilst not specified as an outcome of interest in
the original protocol, it was highlighted as a common secondary
outcome measure in three of the studies included in the final
review. For this reason, we decided to include these data within
the results. Decision conflict measures (1) healthcare consumers’
uncertainty in making a health-related decision; (2) the factors
contributing to the uncertainty; and (3) healthcare consumers’
perceived effective decision making.
These outcomes were quantified using validated or non-validated
questionnaires, ratings, or scales.
Search methods for identification of studies
Electronic searches
Weupdated searches from the previous review (Clarkesmith 2013)
by searching the Cochrane Central Register of Controlled Trials
(CENTRAL) and the Database of Abstracts of Reviews of Effects
(DARE) in The Cochrane Library (January 2016, Issue 1 of 12),
MEDLINE Ovid (1949 to February week 1 2016), EMBASE
Classic + EMBASEOvid (1980 toWeek 7 2016), PsycINFOOvid
(1806 to Week 1 February 2016) and CINAHL Plus with Full
Text EBSCO (1937 to 16/02/2016). See Appendix 1 for the search
strategies.
Searching other resources
We handsearched abstract books from national and international
cardiology, psychology, and psychiatry conferences to include
meetings relating to AF and meetings that discussed the develop-
ment of educational and behaviour change interventions, includ-
ing:
• European Society of Cardiology;
• American College of Cardiology;
• American Heart Association;
• Society for Behavioural Medicine and the Division of
Health Psychology Conference;
• European Health Psychology Conference;
• Royal College of Psychiatrists Annual Meeting.
We also searched dissertation abstracts (UMI ProQuest Digital
Dissertations) and reference lists of all relevant papers to identify
other potentially relevant articles.
We did not apply any language restrictions to the searches.
Data collection and analysis
Selection of studies
Two authors (Clarkesmith and Lane) independently scrutinised
the titles found from the search and decided on inclusion or exclu-
sion. For the 2016 update, two authors (Clarkesmith and Khaing)
independently reviewed the abstracts and papers for inclusion and
exclusion. We used Cohen’s kappa statistic to assess agreement be-
tween the two authors on the selection of articles for inclusion.
At the first review stage (June 2010), the kappa coefficient was
98.4%. Following the updated search in 2012, the kappa coeffi-
cient was 95%. For the current update, the kappa coefficient was
85%. Where disagreements arose, the full-text article was accessed
to determine whether the study met the inclusion and exclusion
criteria and a third author reviewed the studies (Lane). The authors
discussed the article and agreement was reached by consensus.
Data extraction and management
Two review authors independently extracted the data. For each
trial, the following data were extracted (where available) using a
specially designed data extraction form: participants (sample size,
age, sex, ethnicity, marital status, type of AF); type of anticoag-
ulation therapy (VKA, i.e.,warfarin, other); type and duration of
the interventions (intervention versus usual care or no interven-
tion, other combinations); primary (TTR) and secondary out-
comes (increase in knowledge with regard to AF and anticoagu-
lation therapy, decision conflict, time within the therapeutic INR
range, patient satisfaction, acceptability of the anticoagulant ther-
apy, quality of life, changes in perception towards AF and INR
control, changes in the patients’ illness beliefs and illness repre-
sentations, changes in the patients’ beliefs about medications, self-
reported adherence, psychological well-being); length of follow-
up; statistical methods employed; the effect size and its precision.
Studies were included in this review if they reported any of the
primary or secondary outcomes of interest, regardless of whether
the original study’s primary or secondary outcomes corresponded
with the review’s primary or secondary outcomes. For example, if
a study reported TTR as a secondary outcome, we included the
TTR in this review as part of the primary outcome.
Assessment of risk of bias in included studies
Two review authors (Clarkesmith and Lane) independently as-
sessed the risk of bias of each trial in accordance with guidance
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).Wedetermined the risk of bias using theCochrane
’Risk of bias’ tool. We assessed the following criteria.
• Random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias)
and of outcome assessors (detection bias).
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• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other sources of bias.
We judged each criteria as low risk, high risk, or unclear risk.
Sequence generation
• Low risk, if the allocation sequence was generated using
techniques such as a random number table; a computer random
number generator; coin tossing; shuffling cards or envelopes;
throwing dice; or cluster randomisation.
• High risk, if the allocation sequence was generated using
techniques such as odd or even date of birth; date (or day) of
admission; hospital or clinic record number.
• Unclear risk, if there was insufficient information about the
sequence generation process to permit judgement.
Allocation concealment
• Low risk, if the allocation concealment used methods such
as central allocation (including telephone, web-based, and
pharmacy-controlled randomisation); sequentially numbered
drug containers of identical appearance; sequentially numbered
opaque, sealed envelopes.
• High risk, if the participants or investigators enrolling
participants could possibly foresee assignments and thus
introduce selection bias, such as allocation based on using an
open random allocation schedule (e.g. a list of random
numbers); assignment envelopes used without appropriate
safeguards (e.g. if envelopes were unsealed or non-opaque, or not
sequentially numbered); alternation or rotation; date of birth;
case record number.
• Unclear risk, if the method of concealment was not
described or not described in sufficient detail to allow a definite
judgement (e.g. if the use of assignment envelopes was described
but it remained unclear whether envelopes were sequentially
numbered, opaque, and sealed).
Where the method of allocation was unclear, we contacted study
authors to provide further details.
Blinding
• Low risk, if there was no blinding but the review authors
judged that the outcome and the outcome measurement were
not likely to be influenced by lack of blinding; if blinding of
participants and key study personnel was ensured and it was
unlikely that the blinding could have been broken; if either
participants or some key study personnel were not blinded but
outcome assessment was blinded and the non-blinding of others
was unlikely to introduce bias.
• High risk, if there was no blinding or incomplete blinding
and the outcome or outcome measurement was likely to be
influenced by lack of blinding; if blinding of key study
participants and personnel was attempted but it was likely that
the blinding could have been broken; if either participants or
some key study personnel were not blinded and the non-
blinding of others was likely to introduce bias.
• Unclear risk, if there was insufficient information to permit
judgement or the study did not address this outcome (e.g. where
the blinding was described only as double-blind without any
other details).
Incomplete data assessment (loss of participants, for
example with withdrawals, dropouts, protocol deviations)
• Low risk, if there were no missing outcome data; reasons for
missing outcome data were unlikely to be related to the true
outcome; missing outcome data were balanced in numbers across
intervention groups with similar reasons for missing data across
groups; for dichotomous outcome data, the proportion of
missing outcomes compared with observed event risk was not
enough to have a clinically relevant impact on the intervention
effect estimate; for continuous outcome data, plausible effect size
(difference in means or standardised difference in means) among
missing outcomes was not enough to have a clinically relevant
impact on observed effect size; missing data were imputed using
appropriate methods; for cluster randomised trials, an error
made in statistical analysis when the analysis does not take
account of the unit of allocation.
◦ In some studies, the unit of allocation is not a person
but is instead a group of people. Sometimes the data from these
studies are analysed as if people had been allocated individually.
Using individuals as the unit of analysis when groups of people
are allocated can result in overly narrow confidence intervals.
Thus, where included in meta-analysis, it can result in studies
receiving more weight than is appropriate and this must be
accounted for.
• High risk, if the reasons for missing outcome data were
likely to be related to true outcome, with either imbalance in
numbers or reasons for missing data across intervention groups;
for dichotomous outcome data, the proportion of missing
outcomes compared with observed event risk was enough to
introduce clinically relevant bias in the intervention effect
estimate; for continuous outcome data, plausible effect size
(difference in means or standardised difference in means) among
missing outcomes was enough to introduce clinically relevant
bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that
assigned at randomisation; potentially inappropriate application
of simple imputation.
• Unclear risk, if there was insufficient reporting of attrition
or exclusions to permit judgement (e.g. numbers randomised
were not stated, no reasons for missing data were provided), or
the study did not address this.
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Selective outcome reporting
• Low risk, if the study protocol was available and all of the
study’s pre-specified (primary and secondary) outcomes that were
of interest in the review were reported in the pre-specified way;
the study protocol was not available, but it was clear that the
published reports included all expected outcomes including
those that were pre-specified.
• High risk, if not all of the study’s pre-specified primary
outcomes were reported; one or more primary outcomes were
reported using measurements, analysis methods, or subsets of the
data (e.g. sub scales) that were not pre-specified; one or more
reported primary outcomes were not pre-specified (unless clear
justification for their reporting was provided, such as an
unexpected adverse effect); one or more outcomes of interest in
the review were reported incompletely so that they could not be
entered in a meta-analysis; the study report failed to include
results for a key outcome that would be expected to have been
reported for such a study.
• Unclear risk, if there was insufficient information to permit
judgement.
Other sources of bias
• Low risk, if the study appeared to be free of other sources of
bias.
• High risk, if there was at least one important risk of bias
(e.g. the study had a potential source of bias related to the
specific study design used; stopped early due to some data-
dependent process (including a formal stopping rule); had
extreme baseline imbalance; had been claimed to be fraudulent;
had some other problem).
• Unclear, if there was either insufficient information to assess
whether an important risk of bias existed or if there was
insufficient rationale or evidence that an identified problem
would not introduce bias.
Measures of treatment effect
We undertook statistical analyses as follows. For continuous vari-
ables (for example changes in illness perception questionnaire or
changes in TTR), we calculated the mean difference (MD) with
95% confidence interval (CI). Had we been able to pool any di-
chotomous variables, we would have calculated odds ratios (OR)
with 95% CI.
Dealing with missing data
Where the article indicated inclusion of AF patients, but data
were not included by subgroup, we contacted the authors of the
included studies to gather AF-specific data. We also contacted
authors where there was insufficient detail on the demographic
data for AF patients or the content of the intervention. We re-
ceived responses and additional data from several authors (Beyth
2000; Christensen 2007; Clarkesmith 2013; Gadisseur 2003;
Hendriks 2013; Polek 2012; Thomson 2007; Vormfelde 2014).
For fifteen studies the authors could not be contacted (Al-Meshal
2013; Lakshmi 2013; Moore 2013; Sawicki 1999; Stone 1989;
Verret 2012; Watzke 2000) or did not respond to e-mail or writ-
ten requests for unpublished data (Barcellona 2006; Chan 2006;
Gardiner 2006; Jank 2009; Menendez-Jandula 2005; Ryan 2009;
Siebenhofer 2007; Yildirim 2015). For two studies, we successfully
contacted the authors but the data were unavailable (Machtinger
2007; Moss 2014). If authors responded with data that were in-
complete, we contacted them again for further details.
Assessment of heterogeneity
We assessed heterogeneity of studies included in the meta-anal-
ysis using the I2 statistic and Chi2 test for heterogeneity. Data
were considered heterogenous if the P value was less than or equal
to 0.10, for which random-effect models were used. Fixed-effect
models were used where the P value was greater than 0.10.
Assessment of reporting biases
There were not enough studies in this review to test for report-
ing bias, thus we discuss the findings narratively. However, future
revisions will test for bias using a funnel plot based on the data
for the primary outcome of TTR. Asymmetry of the funnel plot
will be taken as an indication of publication bias. Other causes of
asymmetry of the funnel plot will also be explored, such as clini-
cal heterogeneity between studies (for example, different control
event rates) or methodological heterogeneity between studies (for
example, failure to conceal allocation). We summarised informa-
tion on blinding during both the collection and analysis of study
data in a narrative review; this information informed the risk of
bias assessments. We also summarised the completeness of the re-
ported data, including any concerns over the exclusion of partic-
ipants or excessive dropouts. We also reported concerns over the
selective reporting of outcomes, time points, or subgroups.
Data synthesis
We combined results of individual studies within a narrative re-
view. Where possible and appropriate, we used meta-analysis to
statistically combine results. We included TTR data if directly
reported using the Rosendaal method of calculation (Rosendaal
1993), or where available from personal communication with the
authors. For the analysis we used Review Manager to calculate the
summary statistics (RevMan 2014). We examined heterogeneity
using the Chi2 and the I2 statistics (Higgins 2011). We evalu-
ated the quality of evidence using the GRADE approach (Higgins
2011), and we employedGRADE profiler to to create a ’Summary
of findings’ table GRADEpro 2015.
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Subgroup analysis and investigation of heterogeneity
We carried out subgroup analyses looking at the type of interven-
tion (educational alone, behavioural alone, and a combination of
education and behavioural versus usual care). Future revisions may
also examine frequency (one session versus multiple sessions) and
duration (less than six months versus more than six months) of the
intervention, length of time on OAT, men versus women, indi-
vidual versus group interventions, and age of participant groups,
dependant upon the availability of such data in the included study
reports.
Sensitivity analysis
There were insufficient studies to carry out sensitivity analyses.
However, future revisions of the review may employ sensitivity
analyses to examine factors that may lead to differences between
the results of individual trials: poor quality versus good quality
trials.
R E S U L T S
Description of studies
Results of the search
The search retrieved 1560 de-duplicated articles from all sources.
Of these, we excluded 1451 by assessing the titles and abstracts.
We obtained 109 full-text articles for consideration.
We excluded 86 articles based on review of the full-texts. Of
these, we included one new study as an ongoing trial. Of the
three ongoing trials included in the previous version of this review
(Clarkesmith 2013), we included two as studies in this review and
excluded one based on subsequent information in the published
results suggesting the trial was not randomised (further details are
given in the Excluded studies section). We included a total of 20
articles reporting on 11 studies in this review (Figure 1). A further
three articles relating to the included studies were found subse-
quent to the searches and are included as references.
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Figure 1. PRIMSA flow chart of included studies.
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Included studies
Thirteen articles reporting on eight studies were included in
the original Cochrane review (Beyth 2000; Christensen 2007;
Gadisseur 2003; Man-Son-Hing 1999; McAlister 2005; Polek
2012; Thomson 2007; Voller 2005). For this update we have iden-
tified a further ten articles reporting on three studies (Clarkesmith
2013; Hendriks 2013; Vormfelde 2014). Two of these studies
were included in the previous review (Clarkesmith 2013) as on-
going trials and now have published results (Clarkesmith 2013;
Vormfelde 2014). Features of the interventions are included in the
Characteristics of included studies. See the PRISMA flow chart
for the inclusion process (Figure 1).
Methods
The 11 included studies were randomised controlled trials. Six of
the studies specifically recruited AF patients (Clarkesmith 2013;
Hendriks 2013;Man-Son-Hing 1999;McAlister 2005; Thomson
2007; Voller 2005). A further five ’mixed’ trials recruited pa-
tients with a range of indications for OAT (for example AF, ve-
nous thromboembolism, cardiovascular disease, heart valve pros-
thesis, peripheral vascular disease, or myocardial infarction) and
the authors provided unpublished data on the AF patients (Beyth
2000; Christensen 2007; Gadisseur 2003; Polek 2012; Vormfelde
2014). Two trials were cluster randomised studies (McAlister
2005; Vormfelde 2014), and one used a Zelen design (Gadisseur
2003).
Participants
The total sample size of 2246 AF patients, including published
and unpublished data, varied by trial from 14 to 712 participants
(Polek 2012 (unpublished), andHendriks 2013, respectively). The
mean age of the trial participants, from studies that reported age,
ranged from 59 to 75 years. One trial did not provide any demo-
graphic information for their AF patients (Gadisseur 2003).
Patients were included if they had AF (Clarkesmith 2013;
Hendriks 2013; McAlister 2005; Thomson 2007; Voller 2005);
had ECG documented AF (Clarkesmith 2013; Hendriks 2013);
were receiving intravenous heparin (Beyth 2000); were aged 18
years or over (Christensen 2007; Clarkesmith 2013; Hendriks
2013; McAlister 2005), 60 years or over (Thomson 2007), 65
years or over (Beyth 2000), or 18 to 75 years (Gadisseur 2003);
planned to start warfarin (Beyth 2000; Gadisseur 2003; Polek
2012; Thomson 2007); had been taking warfarin for any length
of time (Thomson 2007; Vormfelde 2014), greater than three
months (Gadisseur 2003), less than 3months (Clarkesmith 2013),
or greater than eight months (Christensen 2007); were accessi-
ble via telephone (Polek 2012); and had German language skills
(Vormfelde 2014).
Patients were excluded if they had been treated with warfarin at
any time in the previous six months (Beyth 2000); had contraindi-
cations for warfarin (Clarkesmith 2013); previously received war-
farin (Clarkesmith 2013); were admitted from a nursing home
(Beyth 2000; Polek 2012); were enrolled in another clinical trial
(Beyth 2000; Voller 2005); were too ill to give consent (Beyth
2000) or did not speak English (Beyth 2000; Clarkesmith 2013;
McAlister 2005; Polek 2012; Thomson 2007); had previously
used self-management for INR (Christensen 2007); had antiphos-
pholipid syndrome (Gadisseur 2003), a life threatening illness
(Gadisseur 2003), life expectancy less than or equal to one year
(Clarkesmith 2013; Gadisseur 2003; McAlister 2005), cognitive
impairment (Clarkesmith 2013; Gadisseur 2003;McAlister 2005;
Polek 2012; Thomson 2007), physical limitations making suc-
cessful participation impossible (Gadisseur 2003), or poor hear-
ing or eyesight (Voller 2005); had experienced a major haem-
orrhage in a previous trial (Man-Son-Hing 1999); were taking
warfarin for another condition (McAlister 2005; Thomson 2007;
Voller 2005); were scheduled for cardioversion (McAlister 2005;
Thomson 2007) or cardiac surgery (Vormfelde 2014); had a his-
tory of psychotic disorder (Polek 2012), previous stroke or tran-
sient ischaemic attack (TIA; Thomson 2007), valvular heart dis-
ease (Clarkesmith 2013), unstable or uncontrolled hypertension
(Vormfelde 2014), unstable heart failure (Vormfelde 2014), un-
treated hyperthyroidsim (Vormfelde 2014), current or forseen
pacemaker (Vormfelde 2014), internal cardioverter defibrillator
(Vormfelde 2014), or alcohol or other addiction (Voller 2005).
Types of studies
Of the eleven studies that were identified, five compared education
with usual care (Clarkesmith 2013; Gadisseur 2003; Hendriks
2013; Polek 2012) or usual care with an educational booklet
(Vormfelde 2014), four compared self-monitoring plus educa-
tion with usual care (Beyth 2000; Christensen 2007; Gadisseur
2003; Voller 2005), and one also included a self-management
group (Gadisseur 2003). A further three trials focused on the
use of a decision support aid versus usual care (Man-Son-Hing
1999;McAlister 2005) or a ’guideline evidence’ comparison group
(Thomson 2007).
Types of interventions
Interventions were either one to one (Beyth 2000;Hendriks 2013;
McAlister 2005; Polek 2012; Vormfelde 2014) or group training
sessions (Gadisseur 2003; Voller 2005), or both (Clarkesmith
2013). Three of the trials did not explicitly specify a group or
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individual intervention type (Christensen 2007; Man-Son-Hing
1999; Thomson 2007).
All of the interventions included an educational element, usually
consisting of a description of the consequences of minor or ma-
jor stroke and major haemorrhage, the blood monitoring required
for VKA (i.e. warfarin), and the probability of stroke and ma-
jor haemorrhage for patients taking a VKA. Most interventions
also included information regarding the lifestyle factors influenc-
ing VKA control and provided written educational materials or a
booklet. Two of the interventions also included a video compo-
nent (Clarkesmith 2013; Vormfelde 2014). Self-monitoring inter-
ventions included training on the use of INR monitoring devices
(Beyth 2000; Christensen 2007; Gadisseur 2003; Voller 2005).
Decision aid interventions offered more detailed information
on the risks of bleeding and thromboembolism (Man-Son-Hing
1999;McAlister 2005; Thomson 2007). All three trials using a de-
cision support aid employed pictograms to depict the risk of stroke
and bleeding on either placebo, aspirin, or warfarin; two utilised
paper-based charts (Man-Son-Hing 1999; McAlister 2005) and
the third used a computerised version (Thomson 2007). The de-
cision aid was presented and patients were asked to select which
treatment they would prefer on the basis of the risk information
presented in the pictogram (probability trade-off technique). For
example, the consequences of a minor stroke, a major stroke, and
minor and major bleeding were described along with the proba-
bility of those events occurring whilst taking different treatment
options. This gave patients the opportunity to make informed de-
cisions (Man-Son-Hing 1999); in this trial patients completed a
worksheet which summarised the information following use of the
decision aid.
Duration of the intervention
The duration of the educational training element of the inter-
ventions varied. Seven trials reported a one-off consultation of 30
to 60 minutes (Beyth 2000; Clarkesmith 2013; Thomson 2007;
Vormfelde 2014) or three to four sessions each lasting 30 to 120
minutes (Gadisseur 2003;Hendriks 2013;Voller 2005). The other
four trials did not specify how long the intervention lasted or
the number of sessions (Christensen 2007; Man-Son-Hing 1999
McAlister 2005; Polek 2012).
Intervention facilitator
Two studies did not specify the type of facilitator (Christensen
2007; Voller 2005). Of those that did, facilitators included a lay
educator (Beyth 2000); a physician, pharmacist, or healthcare pro-
fessional (Gadisseur 2003; McAlister 2005; Polek 2012); a com-
puterised audio tool (Man-Son-Hing 1999; Thomson 2007); a
trainee health psychologist (Clarkesmith 2013); a practice nurse
(Vormfelde 2014); and a nurse specialist (Hendriks 2013).
Country
The geographical settings of the studies were: Denmark (
Christensen 2007), the Netherlands (Gadisseur 2003; Hendriks
2013), Germany (Voller 2005; Vormfelde 2014), USA (Beyth
2000; Man-Son-Hing 1999; Polek 2012), Canada (McAlister
2005), and the UK (Thomson 2007; Clarkesmith 2013).
Setting for the intervention
Most of the interventionswere conducted in a hospital or anticoag-
ulation clinic setting (Beyth 2000; Christensen 2007; Clarkesmith
2013; Gadisseur 2003; Hendriks 2013; Man-Son-Hing 1999;
Polek 2012). Two of the trials took place in general practitioner
(GP) practices (McAlister 2005; Vormfelde 2014), with another
taking place in a research clinic with patients from general prac-
tices (Thomson 2007). One of the trials did not describe the in-
tervention setting (Voller 2005).
Follow-up
Assessment of the impact of the intervention on outcomes
was at three (Polek 2012), six (Beyth 2000; Christensen
2007; Clarkesmith 2013; Gadisseur 2003; Man-Son-Hing 1999;
Vormfelde 2014), and 12 months (Clarkesmith 2013; Hendriks
2013; McAlister 2005; Thomson 2007).
Funding
Four of the trials declared some funding input by drug companies
(Clarkesmith 2013; Gadisseur 2003;Man-Son-Hing 1999; Voller
2005).
Excluded studies
We excluded 86 studies for the following reasons.
1. Twenty-one studies were excluded for not providing a break-
down of a mixed indication cohort per indication (Al-Meshal
2013; McCahon 2011; Moore 2013; Nilsson 2011; Suriano
2014; Vadher 1996; Vadher 1997; Verret 2012), or not includ-
ing AF patients (Baker 1991; Bump 1977; Claes 2005; Claes
2006; Cordasco 2009; Cromheecke 2000; Cromheecke 2001;
Fitzmaurice 2005; Holbrook 2007; Landefeld 1992;Mazor 2007;
Pernod 2008; Waterman 2001).
2. Fourteen studies did not provide AF-specific findings, and at-
tempts to obtain the specific data from the authors were unsuc-
cessful. For twelve of these studies the authors could not be con-
tacted (Lakshmi 2013; Stone 1989; Sawicki 1999; Watzke 2000),
or did not respond to e-mail or written requests for unpublished
data (Barcellona 2006; Chan 2006; Gardiner 2006; Jank 2009;
Menendez-Jandula 2005; Ryan 2009; Siebenhofer 2007; Yildirim
2015). For two studies, the author was successfully contacted but
the data were unavailable (Machtinger 2007; Moss 2014).
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3. Thirty-one studies were not RCTs (Armstrong 2011; Bajorek
2005; Blaise 2009; Bloomfield 2011; Burns 2009; Castelino 2010;
Corbella 2009; Davis 2005; Duran-Parrondo 2011; Fraenkel
2011; Hasan 2011; Heidbuchel 2015; Krause 2010; Leger 2004;
Megden 1999; Morin 2015; Nedaz 2002; Polzien 2007; Qvist
2016; Reverdin 2011; Saokaew 2010; Satger 2009; Sawicki 2003;
Stafford 2011; Taylor 1997; Tuiskula 2011; Turc-Dessertine 2005;
Winans 2010; Witt 2005; Woodend 2005; Wurster 2006).
4. Nineteen studies did not fulfil other predefined inclusion cri-
teria. Seven did not include an educational or behavioural in-
tervention (Field 2010; Fitzmaurice 1996; Fitzmaurice 2000;
Gouin-Thibault 2010; Matchar 2005; Trivalle 2010; Waterman
2001 b). Five studies provided education on self-monitoring alone
with no additional education on AF and the risks and benefits
of OAT (Christensen 2011; Dolor 2010; Grunau 2011; Matchar
2010; Sunderji 2005). None of the studies were excluded for in-
cluding participants <18 years of age. Five studies did not report
any of the pre-specified outcomes (Batty 2001; Jackson 2004;
O’Sullivan 2016; PRISM Study group 2003; Peng 2014). One of
the studies did not randomise their usual care group (Khan 2004).
One of the studies did not have a separate control group; patients
acted as their own historical control (Bereznicki 2013).
5. One study eligible for inclusion is an ongoing trial and the
results are not yet available (Siebenhofer 2012).
Two studies that were excluded from a previous version of this
review as they were ongoing trials are now included (Clarkesmith
2013; Vormfelde 2014), and one has been excluded as it was not
an RCT (Stafford 2011).
Risk of bias in included studies
The risk of bias for each of the included studies is summarised
in Figure 2 and Figure 3. Individual domains are summarized
below, with detailed information for each in the Characteristics of
included studies tables.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Nine of the included trials provided information about adequate
sequence generation. For themajority of trials this consisted of ran-
domisation to the intervention or usual care according to: a com-
puter-generated sequence using block randomisation (Christensen
2007; Clarkesmith 2013; Man-Son-Hing 1999; McAlister 2005;
Thomson 2007); one-to one randomisation (Hendriks 2013); a
random numbers table (Voller 2005); or a two-step partial-Zelen
design (Gadisseur 2003). The other two trials did not provide de-
tails of sequence generation (Beyth 2000; Polek 2012).
Two studies used cluster randomisation at the level of the family
physician (McAlister 2005; Vormfelde 2014). All eligible patients
within any one physician’s practice were allocated to the interven-
tion or usual care practices. This process avoided contamination
that may have occurred if the same physician delivering the inter-
vention also delivered usual care.
All of the studies reported the number of eligible participants;
however, for the mixed cohort trials it was difficult to retrospec-
tively assess which of the screened patients had AF. Of those trials
specifically recruiting AF patients, the percentage of eligible pa-
tients randomised ranged from 15% to 94% (Clarkesmith 2013
and Hendriks 2013, respectively). In the mixed indication co-
hort trials this percentage ranged from 18% to 95% (Gadisseur
2003 and Christensen 2007, respectively). Thus, some of the trials
were more representative than others. Those trials that included
less than 50% of the eligible participants were at risk of selection
bias (Clarkesmith 2013; Gadisseur 2003; Man-Son-Hing 1999;
McAlister 2005; Thomson 2007; Vormfelde 2014), whereby pa-
tient characteristics may affect the study outcomes. For example,
those patients that participated may have been more motivated or
willing to participate. One study did not report how many partic-
ipants were eligible for the study (Voller 2005).
Blinding
Blinding patients to the intervention they were receiving was not
possible with these types of interventions, nor was it possible to
blind the intervention facilitator towhich arm the patients were in.
This inevitably raises the risk of bias for all studies. Experimenter
bias could have occurred in these trials, whereby the individuals
delivering the intervention and usual care could behave differently
towards a group inadvertently, affecting the study outcome. There
was one exception to this (Clarkesmith 2013), where all INRmon-
itoring (primary outcome) was undertaken at an independent an-
ticoagulation clinic where the employees were not aware of the
treatment allocation. However, blinding of the outcome assessors
(the data analysts or researchers) regarding to which intervention
arm the patientwas assignedwas possible, in principle, andwas un-
dertaken in six trials (Beyth 2000; Clarkesmith 2013; Christensen
2007; Gadisseur 2003; Hendriks 2013; McAlister 2005). Five tri-
als did not state whether their outcome assessor was blinded to
the group to which the patients were randomised (Man-Son-Hing
1999; Polek 2012; Thomson 2007; Voller 2005; Vormfelde 2014)
or indeed whether the individual delivering the intervention also
carried out the analysis, which inevitably increases the risk of bias.
Incomplete outcome data
The percentage of patients completing the final follow-up with
data available for all outcomes ranged from 55% to 100%
(Clarkesmith2013 andVoller 2005, respectively). Attrition greater
than 20% was considered to indicate high risk of bias. Attrition
was greater for questionnaire follow-ups than clinical follow-ups
(such as those trials reporting TTR or cardiovascular death as their
primary outcome). If attrition is related to any feature of the study
design or instrumentation, or leads to bias between groups, this
will increase the risk of bias. Some of the self-monitoring and de-
cision aid studies reported participants as lost to follow-up due
to an inability to perform the tests or to understand the decision
aid. Other reasons included discontinuing warfarin, moving away
from the area, death, illness, and hospitalisation. Where patients
were unable to use the intervention, this could lead to a high risk
of bias, compared to a more ’capable’ sample.
Selective reporting
Five of the studies published a protocol paper (Clarkesmith 2013;
Hendriks 2013; McAlister 2005; Voller 2005; Vormfelde 2014).
McAlister and Hendriks reported on all but one of the pre-spec-
ified outcomes (patient satisfaction). Two studies reported on all
of their pre-specified outcomes (Voller 2005; Vormfelde 2014),
although one trial was ended early due to insufficient participant
numbers to power the primary outcome (Voller 2005), Clarke-
smith reported on all pre-specified outcomes other than cost-effec-
tiveness (Clarkesmith 2013). A further six studies did not publish
protocol papers (Beyth 2000; Christensen 2007; Gadisseur 2003;
Man-Son-Hing 1999; Polek 2012; Thomson 2007), but reported
on all the outcomes specified within their method section.
Other potential sources of bias
Over the course of the study, participant characteristics may
change. With increasing age the participants in these studies were
likely to have suffered from additional comorbidities and started
taking newmedications. These trial designs cannot control for the
impact of concomitant medications or the additional burden of
new medication regimens across the study period, thus this may
have increased the risk of bias for all trials. Four trials required
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patients to be able to undertake self-monitoring and/or self-man-
agement of INR (Beyth 2000; Christensen 2007; Gadisseur 2003;
Voller 2005), and therefore these patients may not be representa-
tive of all patients requiringOAT; however, in one study all patients
were aged 65 years or older so the results of this study may be more
generalisable to the mainly elderly AF population (Beyth 2000).
In two trials there was a difference at baseline between groups in
terms of the antithrombotic therapy that patients were receiving
(those already receiving warfarin and those not) which could have
affected patients’ ability to make decisions about treatment (one
of the outcomes was decision conflict; McAlister 2005; Thomson
2007). In one study, improvement in knowledge was dependent
on the GP practice where the patient education was delivered,
most probably due to differences in the patient-nurse discussions
after the video presentation (Vormfelde 2014). In one trial, there
was the possibility of contamination between the intervention and
usual care groups, as physicians could have provided similar in-
formation contained within the educational booklet to the usual
care group during routine clinic visits (Man-Son-Hing 1999).
In two trials, the type of intervention (comprehensive nurse-led;
Hendriks 2013) or the intervention facilitator (health psycholo-
gist; Clarkesmith 2013), could suggest that the results may not be
applicable outside these settings.
Effects of interventions
See: Summary of findings for the main comparison Education,
self-monitoring plus education, and decision aids compared to
usual care for oral anticoagulant therapy in patients with atrial
fibrillation
Various methods of measuring outcomes were employed; this was
the main obstacle when comparing study findings. This was fur-
ther complicated by the different time points at which measure-
ments were taken, depending on the length of the trial. Further,
the included studies differed in type (behavioural and decision
aids) and in their comparator group. Where data were comparable
- that is, using the same measurement tool and type of interven-
tion - we requested AF-specific data if it was not provided in the
published article. We report key results in Summary of findings
for the main comparison, and summarize them below by outcome
and intervention.
Primary outcomes
TTR
The TTR (INR of 2.0 to 3.0) was reported by five trials (Beyth
2000; Christensen 2007; Clarkesmith 2013; Gadisseur 2003;
Vormfelde 2014) as outlined by the Rosendaal method (Rosendaal
1993). One trial reported the TTR in days (Voller 2005). Three
trials reported other indicators of INR control: percentage of in-
range INRs (McAlister 2005; Voller 2005), and combined INR
and complications outcomes (Christensen 2007). Of those studies
reportingTTR, all tested self-monitoring plus education or educa-
tion only interventions (Beyth 2000; Christensen 2007;Gadisseur
2003; Vormfelde 2014), but only two published AF-specific data
(Voller 2005; Clarkesmith 2013) and one of those trials did not
use the Rosendaal method (Voller 2005). Thus, we contacted
the remaining trial authors for AF-specific data, which were pro-
vided by three of the authors (Christensen 2007; Gadisseur 2003;
Vormfelde 2014). We did not request AF-specific data for out-
comes that were not comparable; that is, combined INR and com-
plications outcomes (Christensen 2007).
Education intervention
Four of the included trials compared education only and usual
care (Clarkesmith 2013; Gadisseur 2003; Polek 2012; Vormfelde
2014). Three of these trials reported TTR (Clarkesmith 2013;
Gadisseur 2003; Vormfelde 2014).
Gadisseur 2003 studied a cohort with a mixed indication for OAT
and provided additional unpublished data on the AF cohort for
the three arms of the trial who received INR self-monitoring train-
ing including education: self-management, self-measurement, and
routine care in educated patients. They found that the TTR
was highest in the educated usual care group (mean 75.0%, SD
18.5%), followed by the self-measurement group (mean 70.3%,
SD 18.7%), followed by the educated usual care group (mean
67.1%, SD 26.4%) and lowest in the self-management group
(mean 64.7%, SD 18.3%). These groups were not comparable to
Vormfelde 2014, as there was no control comparator in Vormfelde
2014 that did not receive education. These groups were also not
comparable to Clarkesmith 2013 as the education in Gadisseur
2003 was not AF-specific.
Clarkesmith 2013 studied an AF cohort and found significantly
higher TTR in the intervention group (median 76.2%, interquar-
tile range (IQR) 64.1% to 97.3% ) than the usual care group
(median 71.3%, IQR 51.2% to 84.7%) at six months, but no
significant difference between the groups at 12 months (median
76.0%, IQR 60.5% to 85.0% versus median 70.0%, IQR 62.0%
to 79.0%, respectively).
Vormfelde 2014 recruited amixed indication cohort, but provided
unpublished AF-specific data. TTR was significantly higher in
the intervention group (mean 69%, SD 25.1%) compared to the
brochure only group (mean 64%, 28.2%) at 6-months.
Self-monitoring plus education intervention
Four trials examined the impact of self-monitoring plus education
(Beyth 2000; Christensen 2007; Gadisseur 2003; Voller 2005).
Christensen 2007 recruited patients with multiple indications for
OAT, with only 20 AF patients: 11 receiving self-management
plus education and nine in the usual care group. INR control
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was slightly higher in the intervention group (mean 77.3%, SD
11.6%) than in the usual care group (mean 67.9%, SD 23.5%;
MD 9.3%, 95% CI -7.5% to 26.2%; not significant).
Gadisseur 2003 was also a mixed cohort trial where the authors
provided unpublished data on AF patients. TTR in the self-moni-
toringplus education group (mean70.3%, SD18.7%)was slightly
higher than in the usual care group (mean 67.1%, SD 26.4%;
MD 3.2%, 95% CI -13.7% to 20.2%; not significant).
Beyth 2000 did not provide AF-specific data on TTR outcomes
and thus could not be included in these analyses.
Voller 2005 reported cumulative percentage of time in INR rather
than TTR by the Rosendaal method. TTR in the self-monitoring
group (mean 67.8%, SD 17.6%) was significantly higher than in
the usual care group (mean 58.5%, SD 19.8%).
The fixed-effects pooled analysis of the two studies reporting TTR
using the Rosendaal method of calculation demonstrated that self-
monitoring plus education did not significantly improve TTR
when compared to usual care (MD 6.3%, 95% CI -5.63% to
18.25%; Christensen 2007; Gadisseur 2003; Analysis 1.1; Figure
4).
Figure 4. Forest plot of comparison: self-monitoring plus education versus usual care on time in therapeutic
INR range.
Education versus self-monitoring plus education intervention
One trial compared self-monitoringplus educationwith education
only (Gadisseur 2003).
Gadisseur 2003 provided unpublished data on AF patients that
suggested the TTRwas slightly higher in the education only group
(mean 75.0%, SD 18.5%) than in the self-monitoring plus edu-
cation group (mean 70.3%, SD 18.7%).
Decision aid intervention
One trial reported the percentage of INRs in range (McAlister
2005).
Percentage of INRs within the therapeutic range differed from
TTR as the outcome was not calculated using the Rosendaal
method (Rosendaal 1993). McAlister 2005 found that INR con-
trol deteriorated in the usual care arm over time (INRs were be-
tween 2.0 and 3.0 on 66% of the days at three months versus
70% of the days at baseline), while INR control improved in the
intervention arm (INRs were between 2.0 and 3.0 on 72% of the
days at three months versus 65% at baseline). The between group
difference was statistically significant (P = 0.02). By 12 months,
INR control in both arms had regressed back to baseline levels.
However, the usual care and intervention groups were not well
matched at baseline.
Secondary outcomes
Major and minor bleeding, stroke, and thromboembolic
events
Two studies reported major bleeding, stroke, and thromboem-
bolic events (Beyth 2000; Clarkesmith 2013), and one provided
unpublished AF-specific data (Beyth 2000). None of the stud-
ies reported on minor bleeding. Two studies reported mortality
(Beyth 2000; Hendriks 2013), one specified cardiovascular death
(Hendriks 2013), but the other did not specify if death was due
to a cardiovascular cause (Beyth 2000). Three studies reported
the number of thromboembolic or haemorrhagic complications
(Clarkesmith 2013; Voller 2005; Vormfelde 2014), with one re-
porting specifically on those requiring medical treatment (Voller
2005).
Self-monitoring plus education intervention
One study provided unpublished AF data on major bleeding,
stroke, and thromboembolic events (Beyth 2000). This study
found the number of cases of major bleeding in the self-monitor-
ing plus education group (n = 1, 1.8% of total AF cohort) was
similar to the number of cases in the usual care group (n = 2, 3.7%
of total AF cohort). There were also very few cases of stroke and
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thromboembolic events in the self-monitoring plus education (n =
1, 1.8% of total AF cohort) and usual care (n = 2, 3.7% of total AF
cohort) groups (Beyth 2000). Voller 2005 measured thromboem-
bolic and bleeding events. Two severe haemorrhages occurred in
one patient in the self-monitoring group, and one thromboem-
bolic event occurred in the usual care group.
Increased knowledge with regard to AF and anticoagulation
therapy
Seven trials reported on patient knowledge (Clarkesmith 2013;
Hendriks 2013; Man-Son-Hing 1999; McAlister 2005; Polek
2012; Thomson 2007; Vormfelde 2014). Five trials assessed
knowledge before and after the intervention (Clarkesmith 2013;
Hendriks 2013;Man-Son-Hing 1999;Thomson 2007;Vormfelde
2014), and two only tested knowledge after the intervention
(McAlister 2005; Polek 2012). All trials used different measure-
ment tools for assessing knowledge.
Education intervention
Four trials reported on patient knowledge (Clarkesmith 2013;
Hendriks 2013; Polek 2012; Vormfelde 2014). All trials used dif-
ferent knowledge questionnaires and therefore data could not be
pooled.
Two trials reported on mixed indication cohorts (Polek 2012;
Vormfelde 2014). One trial provided unpublished AF data on
knowledge outcomes (Polek 2012). They found slightly higher
knowledge scores in the intervention group (mean 11.2, SD 1.6)
than the usual care group (mean 10.1, SD 1.7) at the 12-week
follow-up. However, the number of AF patients in this mixed
cohort was too small to draw definitive conclusions. Vormfelde
2014 did not provide AF-specific data on patient knowledge to
include in this review.
Hendriks 2013 found a greater improvement in knowledge be-
tween baseline and 12-month follow-up in the intervention group
(mean 7.21, SD 2.30 versus mean 8.23, SD 2.16, respectively)
than the usual care group (mean 6.91, SD 2.54 versus mean 7.66,
SD 2.09, respectively). Between-group differences were significant
at follow-up (P = 0.028).
Clarkesmith 2013 found no significant differences in knowledge
between baseline and six-month follow-up for the intervention or
usual care groups (median (IQR) score at baseline 6 (5 to 7) in
the intervention group versus 6 (4 to 7) in the usual care group;
at six-month follow-up 7 (6 to 7) versus 7 (4 to 7), respectively).
Decision aid intervention
Two trials reported on patient knowledge (Man-Son-Hing 1999;
Thomson 2007).
Thomson 2007 used an extension of the decision conflict scale
(O’Connor 1995), and found that although knowledge scores af-
ter the intervention had improved slightly, by three-month follow-
up they had returned to pre-intervention levels. There was no sig-
nificant difference between the decision aid and guidelines groups
at any point.
Man-Son-Hing 1999 used a non-validated scale and demonstrated
that patients in the decision aid group had significantly greater
knowledge of treatment-related information than those in the
usual care group (aspirin-related knowledge MD 15.9, 95% CI
4.6 to 27.2, P < 0.001; warfarin-related knowledgeMD14.9, 95%
CI 4.6 to 25.2, P < 0.001).
Patient satisfaction
Four trials included patient satisfaction as a specified outcome (
Gadisseur 2003; Hendriks 2013;Man-Son-Hing 1999;McAlister
2005). However, one trial did not report results for this outcome
(McAlister 2005).
Education intervention
One education trial reported patient satisfaction; however, the au-
thors did not provide AF-specific data for this outcome (Gadisseur
2003).
Decision aid intervention
One trial using a decision aid intervention reported patient sat-
isfaction as an outcome (Man-Son-Hing 1999). They found that
the use of the decision aid did not significantly affect patients’
satisfaction with their physician consultations.
QoL: psychological well-being (anxiety and depression)
Three studies reported on QoL as an outcome (Clarkesmith 2013;
Gadisseur 2003; Hendriks 2013), using three different measure-
ment tools (Brazier 1992; Badia 2007; Sawicki 1999). One of the
trials did not publish AF-specific data for QoL (Gadisseur 2003).
Two trials reported anxiety and depression outcomes (Clarkesmith
2013; Hendriks 2013), measured by the Hospital Anxiety and
Depression Scale (Zigmond 1983). One study reported on anx-
iety alone (Thomson 2007), using a different measurement tool
(Spielberger 1969).
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Education intervention
Two trials reported on anxiety (Clarkesmith 2013; Hendriks
2013). Both trials used the Hospital Anxiety and Depression Scale
to measure anxiety (Zigmond 1983).
Clarkesmith 2013 provided unpublished scores for anxiety. They
found a greater increase in anxiety from baseline to 6 months
in the intervention group (mean 6.14, SD 5.13) than the usual
care group (mean 3.86, SD 6.36), but these differences were not
significant (P = 0.14). There were no significant differences in
anxiety between baseline and 12 months in either the intervention
(mean 2.41, SD 5.28) or usual care (mean 2.71, SD 5.86) groups
(P = 0.86). Between 6 and 12 months there was a slight, but non-
significant (P = 0.24), decrease in anxiety in both the intervention
(mean -3.00, SD 5.33) and usual care (mean -0.35, SD 5.86)
groups.
Hendriks 2013 reported no significant changes in anxiety from
baseline (median 5, IQR 3 to 9) to 12 months (median 5, IQR 3
to 8) in the intervention group. In the usual care group there were
no significant changes in scores from baseline (median 5, IQR
3 to 9) to 12 months (median 4, IQR 2 to 7). They found no
significant differences in anxiety between groups, but a significant
increase within both the intervention (median change -1, IQR -
3 to 1) and usual care (median change -1, IQR -2 to 1) groups
across time (P < 0.001).
The fixed-effects pooled analysis of the two studies reporting anx-
iety using the Hospital Anxiety and Depression Scale (HADS)
demonstrated that education had a small but positive impact on
anxiety when compared to usual care (MD -0.62, 95% CI -1.21
to -0.04, P = 0.04; Clarkesmith 2013; Hendriks 2013; Analysis
2.1; Figure 5).
Figure 5. Forest plot of comparison: education versus usual care on HADS anxiety.
Clarkesmith 2013 provided unpublished data for depression. The
found a similar increase in depression from baseline to 6 months
for the intervention (mean 4.32, SD 3.20) and usual care (mean
4.00, SD 3.20) groups; these differences were not significant (P
= 0.71). The difference in depression was less between baseline
and 12 months in both the intervention (mean 2.88, SD 4.1) and
usual care (mean 2.88, SD 5.15) groups (P = 1.00). Between 6
and 12 months there was a slight, but non-significant (P = 0.55)
decrease in depression in both the intervention (mean -1.73, SD
3.10) and usual care (mean -1.06, SD 2.66) groups.
Hendriks 2013 also provided unpublished data for depression and
found no significant change in depression from baseline to 12
months in the intervention (median 4, IQR 1 to 7 versus median
3, IQR 1 to 6) and usual care groups (median 4, IQR 2 to 7 versus
median 4, IQR 2 to 7).
The fixed-effects pooled analysis of the two studies reporting de-
pression using the HADS questionnaire demonstrated that edu-
cation had a small but positive impact on depression when com-
pared to usual care (MD -0.74, 95% CI -1.34 to -0.14, P = 0.02;
Clarkesmith 2013; Hendriks 2013; Analysis 2.2; Figure 6).
Figure 6. Forest plot of comparison: education versus usual care on HADS depression.
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Two trials reported on QoL (Clarkesmith 2013; Hendriks 2013).
Hendriks and colleagues used the SF-36 questionnaire (Ware
1992), whilst the other used the AF-QoL questionnaire (Badia
2007).
Hendriks 2013 found no significant differences between groups
on any of the SF-36 sub-scales. There were significant changes
within groups across time for vitality (intervention: P = 0.008;
usual care: P < 0.00), physical role (usual care: P = 0.004), bodily
pain (usual care: P = 0.002), emotional role (intervention: P =
0.004), and mental health (intervention: P = 0.001).
Clarkesmith 2013 found no significant differences between or
within groups on any of the AF-QoL subscales.
Decision aid intervention
Only one trial reported anxiety as an outcome (Thomson 2007).
Anxiety fell significantly in both groups pre- to post-clinic, (MD
-4.57, 95% CI -6.30 to -2.84), but there was no evidence of a
significant difference in anxiety between the two groups (F (1, 95)
= 0.001; P = 0.98).
Changes in the patients’ illness beliefs and illness
representations
One study reported on illness perceptions, and beliefs about med-
ications (Clarkesmith 2013).
Education intervention
One study reported on illness perceptions (Clarkesmith 2013).
They found no significant differences between the intervention
and usual care groups on any of the sub-scales.
One study reported on beliefs about medication (Clarkesmith
2013). The usual care group scored higher than the intervention
group on specific concerns about medication and general harm
scales at all time points. There was also a significant difference
between groups in the perception of general harm (F (1, 28) = 4.4;
P < 0.05) and an interaction between time and group for patients’
concerns regarding medication (F (4, 27) = 2.9; P = 0.02). There
was a significant interaction between group and time for patients’
perceptions of the overuse ofmedication (F (4, 28) = 2.4, P = 0.04).
The usual care group perceived medication as more overused than
the intervention group. Scores on the Specific-Necessity sub-scale
of the Beliefs about Medicines Questionnaire were similar for both
groups, but there were no significant differences across time or
between groups.
Economic costs of the intervention (cost-effectiveness)
Two studies measured cost-effectiveness of the intervention (
Clarkesmith 2013; Hendriks 2013), but one study did not report
on this outcome and did not provide data (Clarkesmith 2013).
Education intervention
Hendriks 2013 found the cost-effectiveness acceptability curve for
cost per quality-adjusted life year demonstrated that if willingness
to pay is set at EURO20 000, the possibility of nurse-led care
being cost-effective is 99% compared with usual care. For cost per
life-year a probability of 92.5% is reached at a willingness to pay
of EURO20 000.
Decision conflict
Three studies reported on decision conflict (Man-Son-Hing 1999;
McAlister 2005; Thomson 2007). One of the studies did not have
a usual care arm and therefore was not included in the pooled data
analysis (Thomson 2007).
Decision aid intervention
Three studies (Man-Son-Hing 1999; McAlister 2005; Thomson
2007) reported decision conflict, and all used the decision conflict
scale (O’Connor 1995).
Man-Son-Hing 1999 found that the usual care arm (mean 1.74,
SD 0.5) scored slightly higher on decision conflict than the deci-
sion aid arm (mean 1.6, SD 0.4; MD -0.09, 95%CI -0.2 to 0.02).
McAlister 2005 found that the usual care arm (mean 1.7, SD 0.5)
scored slightly higher on decision conflict than the decision aid
arm (mean 1.6, SD 0.5; MD -0.10, 95% CI -0.19 to -0.01).
Although three studies reported decision conflict as an outcome,
only two compared differences in the usual care and decision aid
intervention groups (Man-Son-Hing 1999; McAlister 2005). The
third compared the decision aidwith a guideline comparison group
and therefore was not included in the meta-analysis (Thomson
2007). Data from the two trials were pooled and the random-
effects analysis favoured usual care in terms of reducing decision
conflict (MD -0.10, 95%CI -0.17 to -0.02;Man-Son-Hing 1999;
McAlister 2005; Analysis 3.1; Figure 7).
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Figure 7. Forest plot of comparison: decision-aid versus usual care on decision conflict.
Other outcomes
None of the studies reported on:
• patient acceptability of anticoagulant therapy;
• changes in perception towards AF and INR control;
• self-reported adherence to treatment
D I S C U S S I O N
Summary of main results
This review found eleven RCTs of behavioural and educational
interventions for anticoagulant therapy in patients with AF (Beyth
2000; Christensen 2007; Clarkesmith 2013; Gadisseur 2003;
Hendriks 2013; Man-Son-Hing 1999; McAlister 2005; Polek
2012; Thomson 2007; Voller 2005; Vormfelde 2014). Five trials
compared educationwith usual care (Clarkesmith 2013;Gadisseur
2003; Hendriks 2013; Polek 2012; Vormfelde 2014), four com-
pared self-monitoring plus education with usual care (Beyth 2000;
Christensen 2007; Gadisseur 2003; Voller 2005), and one trial
also compared a self-management group (consisting of self-testing
and self-dosing; Gadisseur 2003). Three trials focused on the use
of a decision support aid versus usual care (Man-Son-Hing 1999;
McAlister 2005) or a comparison group (Thomson 2007). The
analyses included a small number of trials with small sample sizes,
thus more evidence is needed to draw definitive conclusions.
Education
We have summarised the findings from the education trials in
Summary of findings for themain comparison. Two trials compar-
ing education and usual care reported on anxiety and depression
(Hendriks 2013; Clarkesmith 2013). Pooled data demonstrated
that education had a small but positive impact on anxiety (MD
-0.62, 95% CI -1.21 to -0.04, P = 0.04) and depression (MD -
0.74, 95% CI -1.34 to -0.14, P = 0.02) when compared to usual
care over 12 months (Analysis 2.1; Analysis 2.2; Figure 5; Figure
6). These findings are influenced by the weighting of the trial by
Hendriks and colleagues, and the 12 month follow-up data for
both trials, as Clarkesmith 2013 found a decline in both anxiety
and depression in both groups at the 6month follow-up. Evidently
patients may feel more anxious and depressed in the initial months
following diagnosis and treatment commencement.
Self-monitoring plus education versus usual care
We have summarised the findings from the self-monitoring trials
in Summary of findings for the main comparison. Two self-mon-
itoring plus education trials reported TTR (Christensen 2007;
Gadisseur 2003). Pooled data for the AF patients demonstrated
that self-monitoring plus education did not significantly improve
TTR when compared to usual care (MD 6.3, 95% CI -5.63 to
18.25; Analysis 1.1; Figure 4). One previous Cochrane Review
compared self-management (monitoring and dosing) and self-
monitoring (monitoring only) interventions for mixed indication
patients taking OAT (Garcia-Alamino 2010). In their pooled data
analysis, self-management interventions showed significant reduc-
tions in both thromboembolic events (RR 0.50, 95% CI 0.36 to
0.69) and all-cause mortality (RR 0.64, 95% CI 0.46 to 0.89),
but self-monitoring did not. The findings from the current review
support those by Garcia-Alamino 2010 that in an AF cohort, self-
monitoring is no more successful in increasing INR control than
usual care.
Decision aids
We have summarised the findings from the decision aid trials in
Summary of findings for the main comparison. Decision aid trials
favoured usual care over the intervention in minimising decision
conflict (MD -0.10, 95% Cl -0.17 to -0.02; Analysis 3.1; Figure
7). The use of a decision aid did not have a significant impact on
AF patients’ anxiety levels (Thomson 2007) or patient satisfaction
(Man-Son-Hing 1999). This suggests that patients that took part
in the decision aid trial were uncertain as to which treatment they
were going to choose.
Overall completeness and applicability of
evidence
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Five of the included trials had mixed indication cohorts (Beyth
2000; Christensen 2007; Gadisseur 2003; Polek 2012; Vormfelde
2014 ), and 14 further trials were excluded as they did not provide
AF-specific data (Barcellona 2006; Chan 2006; Gardiner 2006;
Jank 2009; Lakshmi 2013; Machtinger 2007; Menendez-Jandula
2005; Moss 2014; Ryan 2009; Sawicki 2003; Siebenhofer 2007;
Stone 1989; Watzke 2000; Yildirim 2015). Recruiting patients
with mixed indications for a VKA can be problematic. Patients
often have different INR ranges (for example with valve replace-
ments) and each patient group is unique in their lifestyle and
treatment recommendations. AF patients are often older (Kannel
1998), prescribed treatment on a long-term basis (NICE 2006),
and susceptible to inaccurate beliefs surrounding their illness
(Steed 2010) due to their symptoms being irregular and often un-
recognised (Fuster 2006). Thus, it is essential that interventions
are disease specific, yet only three of the included trials specifically
mentioned educating the patients about AF (Clarkesmith 2013;
Hendriks 2013; McAlister 2005). Without discussing the illness
itself, patients may not understand the need for treatment and the
associated risks of their condition. Those interventions that are
disease specific may prove more successful in targeting the partic-
ular concerns of the target population.
A further consideration is that the participants in these trial cohorts
may exhibit a number of co-morbidities which have not been ac-
counted for; thus, theymay have received similar behaviour change
interventions in the past for conditions such as diabetes, poten-
tially increasing their knowledge and awareness of risk. Therefore,
the results of these trials may not be representative of the effect
a behavioural or educational intervention may have on a sample
of VKA-naive AF-only patients, and we cannot draw conclusions
on the use of interventions for newly referred patients who are
at greatest risk of complications. The majority of AF patients are
elderly and are likely to have had some prior experience making
treatment decisions for other conditions, although the VKA regi-
men is more complex than simply taking medication.
The primary outcome of this review was time spent in therapeutic
range (TTR). Whilst pooled data from the self-monitoring trials
found no improvement in TTR when compared to usual care,
some evidence from the educational intervention trials suggests
providing face-to-face support and resources can significantly im-
prove TTRwhen compared to usual care. Indeed, one decision aid
trial, also providing education, found INR control deteriorated
in the usual care arm over time, but improved in the interven-
tion group (McAlister 2005). The clinical implications of improv-
ing INR control are important as the effectiveness of treatment,
including warfarin, is often undermined by low levels of adher-
ence, and maintaining the therapeutic range of 2.0 to 3.0 is im-
perative for stroke risk reduction (Kirchhof 2016; Morgan 2009;
White 2007). More evidence is needed to identify the specific in-
tervention components that help to improve INR control, so that
these behaviour change techniques can be adopted in the future.
It is important that researchers specify intervention components
in detail, utilising the behaviour change taxonomy, to enable the
progression of research in the field (Michie 2009; Michie 2011;
Michie 2013).
Patients that self-monitor are also educated to ensure they are
able to perform the tests accurately and safely. It is therefore dif-
ficult to determine whether the education or the self-monitoring
is improving health outcomes. Further, patients selected for self-
monitoring tend to be younger, healthier, and better educated.
Thus, they may not be representative of a general AF population
(Garcia-Alamino 2010). Similarly, decision aids provide patients
with education regarding treatment choices; thus, it is difficult
to determine whether increases in knowledge alone may have the
same effect. The delivery of the intervention could also influence
the outcomes. A group-based intervention provides opportunity
for social comparison, which influences patient attitudes towards
their treatment and their perception of social norms.
Most trials recruited patients that had been previously takingOAT.
Whilst some trials included VKA-naive patients (Clarkesmith
2013;Hendriks 2013; Thomson 2007) or inpatients startingOAT
(Beyth 2000; Polek 2012), only one of the trial cohorts were ex-
clusively VKA-naive (Clarkesmith 2013). Experience of taking a
VKA could increase the risk of poor internal validity as patients
may had been receiving OAT treatment long term, for up to 5.5
years prior to receiving the intervention (Christensen 2007), and
may be influenced by their treatment history (for example side
effects). Previous experience of the treatment may also influence
adherence to recommendations, and a patient’s decision to start
taking the treatment in the first place (Holbrook 2005; Lip 2011).
Patients may develop specific beliefs about their medications that
influence the decision-making process, such as the inconvenience
of regular blood tests, need for reductions in or abstinence from
alcohol, and dietary restrictions (Dantas 2004; Lane 2006; Lip
2007; Lip 2011). Patients may also feel a level of protection from
harm by taking a treatment (Lip 2011), thus increasing their like-
lihood of adopting one treatment over another. One of the trials
in this review recruited patients that had previously taken part in
Man-Son-Hing 1999. All of these patients had previously taken
either an antiplatelet drug (60% of decision aid group versus 60%
of the usual care group) or OAT (37% of the decision aid group
versus 38% of the usual care group). The participants within this
trial are unlikely to be representative of patients that are making
treatment decisions for the first time. Firstly, they are ex-trial pa-
tients and may be more likely to have had prior treatment-related
education and, secondly, they have had first-hand experience of
one or both treatments. One study found that more patients chose
warfarin in a decision aid trial when the drug name was blinded
than when it was unblinded (Holbrook 2007), suggesting that
patients are influenced by prior knowledge, beliefs surrounding
medications, and perhaps any adverse events they may have suf-
fered from. In two studies included in this review (McAlister 2005;
Thomson 2007), there was a difference at baseline between groups
regarding the antithrombotic therapy that patients were receiving
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(those already receiving warfarin and those not) which could have
affected patients’ ability to make decisions about treatment, as one
of the outcomes was decision conflict. Research suggests that pa-
tients are more likely to choose their current treatment over and
above another; it has been suggested that this act prevents cog-
nitive dissonance (that is the stress of choosing a preferred treat-
ment over actual treatment choice; Fuller 2004; Holbrook 2007;
Howitt 1999; Protheroe 2000).
Quality of the evidence
Two types of bias were most prevalent within the studies. Firstly,
blinding of patients to the intervention received was not possible,
nor was it possible to blind the intervention facilitator, inevitably
raising the risk of bias. It is unclear whether the researchers may
have biased patient outcomes by treating the patients in the inter-
vention arm differently from those in the control group. Blind-
ing the outcome assessor (data analyst or researchers) regarding to
which intervention arm the patient was assigned was undertaken
in six trials (Beyth 2000; Christensen 2007; Clarkesmith 2013;
Gadisseur 2003; Hendriks 2013; McAlister 2005). Trial authors
must be explicit when reporting their methods and procedures to
ensure accurate assessment of blinding bias and enable compari-
son of trials.
Inclusion bias was also evident in many studies, where the trial
participants may not have been representative of the eligible par-
ticipants. The percentage of eligible patients randomised was as
low as 15% in the exclusively AF populations (Clarkesmith 2013),
and 18% in one of the mixed cohort trials (Gadisseur 2003). Per-
haps the reluctance of individuals to participate may relate to the
extensive training required, particularly for self-monitoring trials,
or questionnaire burden. Furthermore, many patients may refuse
consent due to physical limitations, the time commitment asso-
ciated with multiple training sessions or multiple follow-ups, or
psychological barriers to performing self-monitoring. AF patients
in particular are mostly elderly (Kannel 1998), and often highly
symptomatic (Lip 2011), thus trial participation may be a burden.
This could explain the small AF sample sizes in the includedmixed
OAT indication trials, as patients with other indications may be
younger and with fewer co-morbidities.
The quality of care in the control groups may vary substantially
within and between countries, and the lack of a ’standard’ of usual
care is one of the key limitations of the studies in this field. There
is no standard provision of anticoagulation monitoring, thus trials
are often comparing an intervention with an unknown entity. The
educational element of the intervention may be one of the key
factors in improving TTR. However, trials varied in the intensity,
duration, and number of education sessions, and the education
facilitator; thus, we cannot draw conclusions about the influence
of each of the educational components or the facilitator of these
interventions on outcomes.
Five studies did not record patients’ level of education (Christensen
2007; Gadisseur 2003; Polek 2012; Thomson 2007; Voller 2005),
a factor which may impact on knowledge uptake and treatment
control. Research suggests that patients with greater knowledge of
their treatment spend more time in the therapeutic range (Tang
2003). Thus, the results of the trials that do not indicate education
level may be influenced by individual differences in educational
achievement between trial groups.
Whilst the educational components of the interventions did focus
on important areas of risk (that is, side effects and medication rec-
ommendations), only three of the trials included education spe-
cific to the patient’s indication for treatment (Clarkesmith 2013;
Hendriks 2013; McAlister 2005). Studies suggest that AF patients
have limited knowledge of their condition (Coehlo-Dantas 2004;
Lane 2006; Lane 2015; Nadar 2003; Tang 2003), which may in-
fluence the perceptions they form about their illness and their
treatment (Steed 2010). Thus, it is essential that patients form
accurate concepts of their illness and make appropriate lifestyle
changes.
Few studies provided AF-specific data on psychological outcomes
such as anxiety, depression, and QoL. Those that did found ele-
vated levels of anxiety and depression for AF patients in both the
intervention and usual care groups (Clarkesmith 2013; Hendriks
2013). Whilst levels decreased over time, there is no evidence that
this change is specifically related to the intervention. The decision
aid trial that reported anxiety as an outcome also found that anx-
iety fell significantly in both groups from pre- to post-clinic (MD
-4.57, 95% CI -6.30 to -2.84), but there was no evidence of a
significant difference in anxiety between the two groups (F (1, 95)
= 0.001; P = 0.98; Thomson 2007). While there is evidence to
suggest that AF patients suffer from high levels of anxiety (Thrall
2004), none of the interventions in this review were designed with
this in mind. Thus the trials exhibit small reductions in anxiety in
the intervention groups versus usual care. As evidence suggests that
AF patients often have inaccurate illness representations (Steed
2010), more trials of interventions that include targeted psycho-
logical components and outcome measures are needed.
Potential biases in the review process
Our search strategy included a comprehensive search of several
electronic databases, meticulous handsearching of reference lists
of included and excluded papers, recent conference proceedings,
and personal communications with experts in this area. In addi-
tion, we wrote to all the authors of included studies requesting
AF-specific data and further demographic and clinical details on
the included cohorts. Further, the titles and abstracts of all studies
identified by the search strategy were reviewed independently by
two review authors and disagreements were resolved by consensus.
Data extraction of the included studies was also undertaken inde-
pendently by two review authors. Therefore, we believe that the
potential for bias in the review process was minimal and that it is
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unlikely that we have missed important studies. It is also impor-
tant to note that the authors of Clarkesmith 2013 are also authors
of this review; for further details see the Declarations of interest.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Patients participating in both educational interventions and self-
monitoring interventions (with education) appear to spend more
time within the therapeutic INR range, but pooled analyses of the
AF data did not significantly favour self-monitoring plus educa-
tion over usual care. Evidence is limited, as there were few trials
with small samples of AF patients. More trials are needed to ex-
amine the impact of intensive educational interventions on anti-
coagulation control in AF patients and the impact on TTR. Self-
monitoring may not be a feasible option for many patients, partic-
ularly as it requires additional training and is costly (Fitzmaurice
2000), and new anticoagulants are now available which do not
require monitoring (Lip 2011; Shantsila 2010). Further, NOAC
trials - for example, where dabigatran was compared with warfarin
- examined the TTR of those patients taking warfarin and com-
pared the event rates by quartile of centre TTR (cTTR; Wallentin
2010). Despite very good cTTR (> 72.6%), both doses of dabiga-
tran were associated with fewer adverse events than warfarin. De-
spite the increasing use of NOACs there are still be some patients
for whom the NOACs are not suitable (for example, those with
severe renal impairment), where a VKA would be the only alter-
native OAT treatment. However, no study to date has compared
self-monitoring with a VKA to treatment with NOACs on ad-
verse events (stroke and major bleeding) and therefore it is unclear
whether there would be a benefit of self-monitoring with a VKA
(in the appropriate patient) over treatment with NOACs. Given
that NOACs are increasingly used to treat AF patients, there is
a need for interventions to provide effective illness-specific edu-
cational tools, which incorporate relevant behaviour change tech-
niques (Michie 2011; Michie 2013).
Implications for research
This review highlights the need for AF-specific trials of educa-
tional/behavioural interventions in larger cohorts and the develop-
ment of psychological interventions for psychological morbidity
in this population. Further, interventions should specifically state
which behaviour change techniques they have used (and why) and
their effect, in order to allow conclusions about which factors are
likely to impact upon adherence. The number of VKA-naive AF
patients within the trials was limited, with most patients being
VKA-experienced. Trials also need to consider the use of disease-
specific measuring tools, which may provide a more accurate as-
sessment of the impact of the intervention. In addition, such trials
should account for the potential confounding effects of level of
education and the quality of the care in the control group.
Ongoing trials
A trial focusing on self-management is currently being undertaken
(Siebenhofer 2012). This trial may provide additional evidence
for later review updates. We will update this review once the re-
sults from this study are published. In addition, for the results to
be generalisable to the AF population there is a need for popula-
tion-based studies that collect data on adverse event rates, time in
therapeutic range, and cost effectiveness, and factors that impinge
on successful educational and behavioural interventions. Future
studies should set out to understand the mechanisms by which in-
terventions are successful by exploring the psychological and prac-
tical implications for AF patients commencing OAT treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beyth 2000
Methods Randomised, controlled, parallel-groups design
Participants N randomised: 132 versus 162 usual care
Diagnosis of patients: AF n = 54 (16.6%) for the intervention group and usual care
groups. Other indications include VTE, cerebrovascular disease, heart valve prosthesis,
peripheral vascular disease, myocardial infarction
Demographics for total cohort:
Age: 74.9±6.9 intervention versus 74.5±6.6 usual care
% female: 55% intervention versus 59% usual care
% white: 69% intervention versus 65% usual care
Mean number of school years 12.1±4.4 intervention versus 12.1±4.1 usual care
Demographics for AF patients:
Age: 74.6±6.8 intervention versus 75.5± 6.2 usual care
% female: 40% intervention versus 66% usual care
% white: 77% intervention versus 77% usual care
Mean number of school years 14.5±4.9 intervention versus 12.0±3.9 usual care
Inclusion/exclusion criteria: Patients hospitalised and receiving 10,000 units or more
of intravenous heparin, were 65 years or over, for whom warfarin treatment was planned
for 10 days or more. Patients were excluded if they had been treated with warfarin at any
time in the previous six months, were admitted from a nursing home, were enrolled in
another clinical trial, were too ill to give consent, or did not speak English
Interventions Type: Guideline-based consultation, education and self-monitoring
Content: A consultation that assessed the patients’ indication for therapy and potential
risks for warfarin-related bleeding (a method used by the researchers previously). This
included specific recommendations about modifiable risk factors, such as use of non-
steroidal anti-inflammatory drugs. The other component included patient education,
coaching, and self monitoring. Patient education consisted of one to one teaching by a
lay educator using a specifically formatted workbook for older adults to teach them about
warfarin, indications for its use, drug and food interactions, and the signs and symptoms
of bleeding. Coaching aimed to increase patients’ participation in their care and improve
information-seeking skills. Self-monitoring of prothrombin time (grounded in social
learning theory). Patients were instructed to monitor 3 times in the first week and once
weekly after that
Duration: 30 minutes to one hour (consultation)
Facilitator: lay educator
Setting: hospital
Outcomes incidence of major bleeding
excessive anticoagulation
rates of VTE
Country Cleveland, Ohio, USA
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Beyth 2000 (Continued)
Comparison usual care group
Length follow-up six months
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were stratified according to their
baseline risk for major bleeding by using
the outpatient bleeding risk index. The in-
dex includes four independent risk factors
for major bleeding: age 65 or older, his-
tory of gastrointestinal bleeding, history of
stroke, and one or more of four specific co-
morbid conditions (myocardial infarction,
hematocrit < 30%, creatinine concentra-
tion> 133µmol/L (1.5mg/dL), or diabetes
mellitus). Patients with one or two risk fac-
tors were classified as intermediate risk, and
those with three or more risk factors were
classified as high risk; estimated frequen-
cies of major bleeding in six months were
6% and 35% respectively. Details on how
patients were assigned to treatment groups
was not reported
Allocation concealment (selection bias) Unclear risk Of the 426 eligible patients identified, 294
(69.0%) received either usual care or the
intervention. Details on how patients were
assigned to treatment groups was not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants cannot be blinded to which
arm of the trial they receive. Neither can
the personnel delivering the intervention
be blinded. However, the educational in-
tervention was delivered by a lay educator
who was not involved in the treatment of
the patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trained abstractors who were not involved
with the intervention component of the
study collected data from the medical chart
at the start of OAT, and by blinded in-
terview at enrolment, at one, three, and
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Beyth 2000 (Continued)
six months after enrolment, and every six
months thereafter. Whenever an event was
reported, the clinical characteristics of the
bleeding or thromboembolic episode were
determined by review of the relevant med-
ical record and abstracted, without identi-
fying the patient, onto a standard form
Incomplete outcome data (attrition bias)
All outcomes
High risk Of the 163 patients assigned to the in-
tervention group, 81% (n = 132) par-
ticipated in the intervention; 12 patients
felt more comfortable with venepuncture,
three stopped warfarin during hospitalisa-
tion, and one was discharged to a nursing
home that precluded the use of a portable
monitor. At six months, 21 patients (13%)
in the intervention group and 26 (16%) of
the usual care group had died
Selective reporting (reporting bias) Low risk The method section describes the primary
outcome as first major bleeding event dur-
ing the six month intervention period. Sec-
ondary outcomes were death and recurrent
VTE at six months; major bleeding after six
months, and INR control during the first
six months of therapy. The authors report
data on all of these outcomes
Other bias Unclear risk All patients had to be able to self-monitor
their INR and therefore the patients may
not be representative of all patients requir-
ing oral anticoagulation. However, all pa-
tients were aged 65 years or older, which is
representative of an AF cohort
Christensen 2007
Methods Open-label randomised controlled trial, cross-over (six months)
Participants N randomised: 47 versus 45 (usual care/conventional management)
AF: n = 11 versus n = 9 (usual care); other indications include mechanical heart valve,
coagulopathies, VTE, synthetic vascular graft
Demographics for total cohort:
Age: 51.5±14.4 intervention versus 46.3±13.4 usual care
% female: 23% intervention versus 44% usual care
% white: not stated
% education above primary level: not stated
Demographics for AF cohort:
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Christensen 2007 (Continued)
Age: 59±18 intervention versus 51±12 usual care
% female: 0% intervention versus 7% usual care
% white: 100% in both groups
% high school or greater: 4% intervention versus 3% usual care
Inclusion/exclusion criteria:
Patients were eligible if they were referred for patient self-management by a general
practitioner or hospital department, treated with oral anticoagulants > 8 months, 18
years or over, and willing to be randomised. Patients were excluded if they had previously
used self-management or lived abroad
Interventions Type: teaching lesson (not explained in detail) and patient self-management
Content:The groupusedCoagucheck,which displays the INRvalue after the application
of a drop of blood. Self-management training included the patient practicing analysis of
blood specimens. The patient gradually assumed management of OAT. After 27 weeks,
patients took an exam; if passed, patient went on to self-manage. After six months the
conventional management group started the same training
Duration: not stated
Facilitator: not stated
Setting: hospital
Outcomes major complications (bleeding and thromboembolism requiring intervention)
death and/or discontinuation of the study
primary endpoint: variance of INR in trial and control samples
TTR
Country Aarhus, Denmark
Comparison conventional management
Length follow-up Observation period
1) 8 to 12 months before randomisation
2) primary observation period was 6 months of either patient self-management or con-
ventional management
3) patient self-management training was 27 weeks
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly assigned to pa-
tient self-management using a comput-
erised, prospective randomisation sched-
ule. Randomisation in blocks with various
sizes in numbers of two, four, and six was
used
41Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Christensen 2007 (Continued)
Allocation concealment (selection bias) Low risk Of the 105 patients who were eligible to
take part in the study, 100 patients were
randomised (95%), therefore there is a low
risk of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Due to the nature of the intervention,
the participants receiving the intervention
and the personnel delivering it cannot be
blinded to which arm of the intervention
they are in. It was unclear whether the per-
sonnel delivering the interventionwere also
involved in treating the usual care arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk External control blood samples were
blinded. The results of the INR analysis
were blinded for all except one secretary
who would ensure the safety of the patient
by contacting themanagingphysician if the
INR value was below 1.5 or above 4.5
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the self-management arm, three patients
dropped out, two during the training pe-
riod, and one died. In the usual care arm of
the study, one patientwaswithdrawnby the
physician and four dropped out during the
self-management training. Thus 92% of
original cohort participants were included
in the analysis
Selective reporting (reporting bias) Low risk The endpoints were the variance (mean
square of standard deviation) of the INR
value, the median INR value (using a
blinded control sample analysed monthly
by a reference laboratory) and the coumarin
dose. All outcomes were reported
Other bias High risk All participants had to be eligible for self-
management of oral anticoagulation and
therefore may not be representative of all
patients requiring oral anticoagulation
Clarkesmith 2013
Methods Randomised controlled trial
Participants N randomised: 46 intervention versus 51 usual care
Diagnosis of patients: All warfarin-naive AF patients
Demographics for total cohort:
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Clarkesmith 2013 (Continued)
Age: 72.0±8.2 intervention versus 73.7±8.1 usual care
% female: 32.6% intervention versus 37.3% usual care
% white: 100% intervention versus 98% usual care
% education above primary level: not stated
Inclusion/exclusion criteria:Newly diagnosedAFpatients referred for warfarin therapy,
with ECG-documented AF. Patients were excluded if they were aged < 18 years, had
any contraindication to warfarin, had previously received warfarin, had valvular heart
disease, were cognitively impaired, were unable to speak or read English, or had any
disease likely to cause their death within 12 months
Interventions Type: one-off, group (one to six patients), theory-driven educational intervention
Content: The intervention involved one group session for one hour where patients
were shown a DVD containing information about the need for OAT, risks and benefits,
potential interactions with food, drugs and alcohol, and the importance of monitoring
and control of their INR. Patients were encouraged to ask questions and complete a
worksheet-based exercise following each 10 minute DVD section. They were then given
educational materials such as a booklet and a self-monitoring INR and lifestyle diary to
take home
Usual care involved patients receiving the standard ’yellow booklet’ which contains
generic information for all patients taking OAT and key safety information
Duration: one hour session
Facilitator: health psychologist (could be delivered by trained lay educator)
Setting: hospital outpatients clinic
Outcomes TTR, knowledge, illness perceptions, beliefs about medication, anxiety and depression,
quality of life, stroke, thromboembolic events, major and minor bleeding
Country United Kingdom
Comparison usual care
Length follow-up 12 months
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer generated list stratified by (a) age (< 70 and >
70 years)/sex and (b) specialist AF clinic versus ‘general’
cardiology clinic, in blocks of four, randomised patients
on an individual basis to receive either ‘usual care’ or the
intensive educational intervention in addition to ‘usual
care’. The randomisation schedule was designed by an
independent trials unit
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Clarkesmith 2013 (Continued)
Allocation concealment (selection bias) High risk Of the 646 patients whowere eligible for the study, 97 pa-
tients participated (15%); 234 (36.2%) eligible patients
declined to participate, primarily due to the question-
naire burden. Due to the number of patients declining
to participate, there is an increased risk of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Due to the nature of the intervention, the patients and
staff delivering the intervention could not be blinded re-
garding to which arm of the trial participants were as-
signed. However, monitoring of the INR (for the pri-
mary outcome, TTR) was undertaken independent of
the study, by the Anticoagulation Services at the hospi-
tals (who were not aware of the patients’ allocation to
intervention or usual care)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The researcher analysing the data was blinded regard-
ing to which arm of the intervention patients were ran-
domised. A researcher not involved in the data analysis or
intervention delivery matched patient ID numbers with
randomisation codes and checked follow-up question-
naires for completeness
Incomplete outcome data (attrition bias)
All outcomes
High risk Ninety-seven patients were randomised to the study; one
discontinued from the intervention arm due to mental
health problems and one discontinued from the usual
care arm due to questionnaire burden. Results were anal-
ysed based on the intention-to-treat analysis for the pri-
mary outcome (TTR). The number of patients returning
questionnaires assessing the secondary outcomes was 62.
9% at six months and 54.6% at twelve months
Selective reporting (reporting bias) Low risk All specified outcomes other than cost-effectiveness were
reported
Other bias Unclear risk The intervention was delivered by a health psychologist
and therefore the results may not be generalisable to dif-
ferent intervention facilitators
Gadisseur 2003
Methods Multicentre randomised study, four arms
Participants N randomised: A) weekly self-measurement n = 52; B) weekly self measurement and
self-dosing n = 47; C) educated routine care n = 60; D) existing routine care (not trained)
n = 161. This study used a Zelen design
Diagnosis of patients: AF patients in group A = 6 (11.6%); group B = 9 (19.2%),
group C = 10 (16.6%), and group D = 43 (26.7%). Other indications included deep
vein thrombosis, pulmonary embolism, artificial heart valves, and vascular prosthesis
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Gadisseur 2003 (Continued)
Demographics for total cohort:
Age: mean in group A = 54.8 (25 to 74), B = 53.9 (24 to 75), C = 56 (21 to 73), D =
62 (32 to 75)
% female: A = 23%, B = 32%, C = 40%, D = 46%
% white: not stated
% education above primary level: not stated
Demographics for the AF patients: not provided
Inclusion/exclusion criteria:
At least three months of OAT experience, need for long-term OAT, and aged 18 to 75
years. Patients were excluded if they had antiphospholipid syndrome, a life threatening
illness, life expectancy ≤ 1 year, diminished understanding, and physical limitations
making successful participation impossible
Interventions Type: self-management and self-dosing including education
Content: They received information about the study, the blood coagulation system,
OAT, and the effects of some substances (e.g. alcohol, certain medications, and foods
rich in vitamin K) on OAT. They were also taught how to use the Coagucheck device,
and instructed on oral self-dosing of phenprocoumon and acenocoumarol. This also
contained practical information about working with theCoagucheck, information about
the coagulation system, and theoretical and practical self-dosing training. They were also
given written information on all the topics discussed
Group A: weekly INR self-measurement, but dosing was performed by anticoagulation
clinic physicians. Patients reported their INR values by telephone to the anticoagulation
clinics. Dosing schedules were communicated via telephone
Group B: this group self-managed their OAT, patients informed the anticoagulation
clinic of their INRmeasurements, proposed dosing schedules, and reported any relevant
information or complications. Patients were contacted via telephone to confirm whether
they could adhere to their proposed dosing schedule or if they needed to adjust it
Group C: patients were trained for inclusion in groups A or B but stayed with the
routine care system. Measurements of INR and dosing were done by anticoagulation
clinic physicians, and the interval between INRmeasurements depended on the stability
of the INR values
Group D: patients in this group were unaware of their participation in the study, repre-
senting the existing care system
Duration: three training sessions, groups of four to five, 90 to 120 minutes
Facilitator: delivered by physician, paramedical person
Setting: hospital
Outcomes Quality of OAT determined by number of INR readings in target range; occurrence
of thromboembolic and haemorrhagic complications; patients ability to independently
perform anticoagulant self-dosing
Country Netherlands
Comparison A) weekly self-measurement
B) weekly self-measurement and self-dosing
C) educated routine care
D) existing routine care (not trained)
45Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gadisseur 2003 (Continued)
Length follow-up mean follow-up time 24.5 weeks
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The patients were selected by groups of 40
and randomised to four treatment groups
(A, B, C, and D) following a 2-step partial
Zelen design
Allocation concealment (selection bias) High risk Of the 881 eligible participants, 159 (18%)
were randomised, therefore this study is at
high risk of inclusion bias. 916 patients were
randomly selected by a computer; 35 (3.
9%) were excluded because of intellectual
or physical limitations or because of a life
expectancy of < 1 year
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients who were not randomised to group
D were sent a letter with written informa-
tion about the study (thus not blinded).
Knowledge of the composition of the dif-
ferent groups was restricted to a few nurses
who were also responsible for anonymously
transferring the dosing schedules for group
A and group B patients to standard forms
and faxing them to the other participat-
ing anticoagulation clinics. The patients
and staff could not be blinded regarding to
which arm of the trial participants were as-
signed. The authors do not state whether
those physicians delivering the intervention
also treated the usual care arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The physicians evaluating and correcting
the proposed dosing schedules for group A
and B were unaware of the originators of
these schedules. The INR values of the pa-
tients in routine care groups C and D were
entered into the routine computerised sys-
tem in such a way that the dosing physicians
could not distinguish between these and the
general patient population
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Incomplete outcome data (attrition bias)
All outcomes
High risk Of the original 180 patients randomised to
the study, 116 (64%) completed the quality
of life questionnaires at baseline and follow-
up; 21 patients were withdrawn or ineligible
and the remainder were lost to follow-up
Selective reporting (reporting bias) Low risk Pre-specified endpoints were (1) quality of
OAT represented by the number of INR
readings within target range (TTR); (2)
patients’ ability to independently perform
anticoagulant self-dosing, by number of
dosage corrections made. All specified out-
comes were reported
Other bias High risk All participants had to be eligible for self-
management of oral anticoagulation and
therefore may not be representative of all
patients requiring oral anticoagulation
Hendriks 2013
Methods Randomised controlled trial
Participants N randomised: 356 intervention versus 356 usual care
Diagnosis of patients: all AF patients
Demographics for total cohort:
Age: 66±13 intervention versus 67±12 usual care
% female: 44.7% intervention versus 37.9% usual care
% white: not stated
% education above primary level: not stated
Inclusion/exclusion criteria: All patients of at least 18 years of age who were referred
for AF (documented on ECG) by GPs or non-cardiology specialists to their outpatient
department were included. Exclusion criteria were any comorbidity which is unsatisfac-
torily treated, unstable heart failure defined as New York Heart Association IV or ne-
cessitating hospital admission < 3 months before inclusion, untreated hyperthyroidism,
current or foreseen pacemaker, internal cardioverter defibrillator or cardio resynchroni-
sation therapy, or cardiac surgery < 3 months before inclusion
Interventions Type: enhanced educational intervention
Content: The intervention consisted of nurse-led outpatient care steered by decision
support software based on the guidelines and supervised by a cardiologist. During the
visits, the nurse specialist informed patients about the pathophysiology of AF, its symp-
toms and possible complications, the results of the diagnostic tests, and treatment op-
tions. The dedicated software CardioConsult AF was used to determine the individual
patient profile based on symptoms, type of AF, and stroke risk, and it proposed the most
appropriate management. Follow-up visits were scheduled at 3, 6, and 12 months, and
every 6 months thereafter. Patients could contact the nurse in person or by telephone
between planned visited as needed. Patients in the control group received usual care by
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a cardiologist in the outpatient clinic during visits
Duration: 30 minutes per visit
Facilitator: nurse specialist
Setting: Maastricht University medical centre
Outcomes Primary endpoint: composite endpoint of cardiovascular hospitalisation or cardiovas-
cular death
Secondary endpoints: guideline adherence, patient knowledge on AF, quality of life,
patient satisfaction, cost-effectiveness
Country The Netherlands
Comparison usual care (outpatient visits with cardiologist)
Length follow-up at least 12 months
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patientswere randomly assigned tonurse-led care or usual
care by a computer generated one to one randomisation
Allocation concealment (selection bias) Low risk Out of 760 eligible patients, 712 patients participated
(94%). Therefore there is a low risk of inclusion bias. The
groups were well matched without significant differences
in baseline characteristics
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The nurse, patients, and the supervising cardiologist were
not blinded due to the nature of the intervention. The
authors do not state whether those physicians involved
in delivering the intervention also treated the usual care
arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk There was an independent panel of specialists to assess
the primary endpoint. This committee was blinded to
assignment and interim study outcomes. They reviewed
each case independently and held a meeting at the end.
If the decision was non-unanimous, the endpoint was
established by the study chair
Incomplete outcome data (attrition bias)
All outcomes
High risk The final sample included all of the original patients that
were randomised to the study. None of the patients were
lost to follow-up. Patients (n =178)whodidnot complete
the SF-36 at both time-points were excluded. There is
a suggestion that more usual care arm patients did not
complete the SF-36 questionnaires
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Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported with the excep-
tion of patient satisfaction
Other bias Unclear risk This was a nurse-led comprehensive intervention and
therefore the results may not be applicable outside this
setting
Man-Son-Hing 1999
Methods Randomized controlled trial
20 possible SPAF trial centres invited, 14 participated
Participants N randomised: n = 139 intervention (10 lost to follow-up) versus n = 148 control (14
lost to follow-up)
Diagnosis of patients: all AF patients
Demographics of cohort:
Age: intervention mean = 65 versus control mean = 65
% female: intervention 24% versus control 24%
% white: not stated
% education above primary level: intervention 90% high school education or greater
versus control 91% high school education or greater
Inclusion/exclusion criteria: All participants were in the SPAF III aspirin cohort study
and were eligible unless they had high risk criteria or had a major haemorrhage during
the study
Interventions Type: decision aid
Content: 29 page booklet, a personal worksheet (complete pre-intervention), and a
20-minute audiotape that guided the patient through the booklet and worksheet. The
intervention included a description of the consequences ofminor/major stroke andmajor
haemorrhage, the blood monitoring required for warfarin and the 2-year probability of
stroke and major haemorrhage for patients taking aspirin/warfarin using pictograms
Duration: not stated
Facilitator: physician/audio tape
Setting: hospital
Outcomes One to four days after meeting with their physicians patients completed questionnaires:
Patient choices (strength of their decisional input, five-point Likert scale, unvalidated)
Knowledge (23 questions about AF, stroke and treatment, unvalidated)
Expectations (four questions regarding patient expectations of stroke/haemorrhage, un-
validated)
Decisional conflict (decisional conflict scale; O’Connor 1995)
Satisfaction (six questions, five-point Likert scale, unvalidated)
Six-month adherence to their treatment decisions (self-report brief questionnaire, ad-
ministered via telephone, unvalidated)
Country US
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Comparison Control group, usual care, i.e. no change was made to the usual manner in which each
centre communicated the results of the SPAF III study or the way in which the decision
regarding type of antithrombotic was made
Length follow-up six-month follow-up
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated scheme, adminis-
tered from a central location to block se-
quence from previewing. Stratified by cen-
tre and the presence of a history of hyper-
tension
Allocation concealment (selection bias) High risk Of the 657 patients who were eligible for
the trial, 287 participated (43%), giving a
substantial risk of inclusion bias; 24 partic-
ipants were lost to follow-up
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors do not state whether the re-
searcher or personnel were blinded regard-
ing to which arm the participants were ran-
domised.However, we can assume that par-
ticipants and physicians were not blinded
to treatment allocation due to the nature of
the intervention. The authors do not state
whether those physicians delivering the in-
tervention also treated the usual care arm
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The authors do not state whether the per-
sonnel scoring and analysing the question-
naires were blinded to the treatment allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
High risk From 139 patients participating, 87 (63%)
worksheetswere completed.However, all of
the 139patients randomised to the decision
aid were included in the study analysis of
decision conflict
Selective reporting (reporting bias) Low risk Outcome measures were patients’ ability
to make choices regarding antithrombotic
therapy, six-month adherence to decision,
knowledge, decision conflict and satisfac-
tion. There was no protocol paper for this
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study. Only one of the pre-specified out-
come variables in the method section was
not reported (patient satisfaction)
Other bias High risk This was a sub-set of the SPAF III trial
and all patients were receiving aspirin. The
SPAF III study excluded those who had
’high-risk criteria’ (without explanation of
this) and those who had major haemor-
rhage, both of which are likely to affect
opinion about oral anticoagulation and the
ability to make decisions about treatment.
Those who participated had a greater pro-
portion with better education (high school
or greater) compared to those who de-
clined participation and this could have
influenced the ability to make a decision.
There was the possibility of contamina-
tion between the intervention and com-
parator arms as physicians could have pro-
vided similar information which was con-
tained in the educational booklet during
routine clinic visits to patients in the usual
care group
McAlister 2005
Methods Prospective, multicentre, two-arm, cluster randomised trial
Participants N randomised: intervention n = 219 versus control n = 215
Fifty GP practices were randomised to the decision aid group and 52 were randomised
to usual care
Diagnosis of patients: All NVAF (also broken down by type of AF; see paper)
Demographics of cohort:
Age: intervention 73±9 versus control 71±10
% female: intervention 43% versus control 34%
% white: not stated
% completed high school: intervention n = 84 (38%) versus control n = 72 (33%)
Inclusion/exclusion criteria: Community-dwelling patients over the age of 18 were in-
cluded in this study if they had a diagnosis of NVAF (intermittent or chronic) confirmed
by ECG, or prescription for digoxin. They were excluded if they 1) had valvular AF; 2)
were taking warfarin for another condition; 3) were scheduled for cardioversion; 3) had
a contraindication for warfarin or aspirin; 4) had cognitive impairment; 5) had a life
expectancy less than 12 months; 6) could not understand/converse in English
Interventions Type: general education session plus patient decision aid and physician’s manual
Content: 30-page decision aid booklet, personal worksheet, 50-minute audiotape to
guide participants through the booklet and worksheet, and a seven-page physician’s
manual summarising the evidence discussed in the patient booklet with a focus on the
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2001ACCP risk stratification schema and recommendations for antithrombotic therapy.
Four versions of the decision aid were available depending on patients’ baseline stroke
risk. All four versions provide the same background information about AF; the potential
consequences of stroke and major haemorrhage; relative efficacy/bleeding risks with
warfarin and aspirin therapy. Key points are further elaborated upon in the audio-tape.
The one-page worksheet is to be completed by the patient after reviewing the booklet to
clarify their personal values regarding desired outcomes, the therapy they are inclined to
take, their preferred role in the decision process, and any questions they have for their
physician
Duration: not stated
Facilitator: physician
Setting: GP practices
Outcomes Use of appropriate antithrombotic therapy at threemonths, as definedby the 2001ACCP
recommendations. Secondary outcomes include (1) appropriate antithrombotic therapy
at 6 months and 12 months, (2) patient’s readiness to make a choice at baseline (previ-
ously validated questionnaire), (3) patient knowledge after the intervention (multiple-
choice responses used in a previous trial), (4) decisional conflict (decision conflict scale;
O’Connor 1995), (5) acceptability of decision aid (9 questions with variable responses
on a five-point Likert scale), (6) satisfaction (five-point Likert scale), (7) adherence with
therapy (validated Morisky scale with modified five-point Likert scale response)
Country Canada
Comparison usual care
Length follow-up one-year follow-up
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation to intervention or usual
care was carried out according to a com-
puter-generated sequence using clustered
block randomisation (block size of four)
with allocation concealment
Allocation concealment (selection bias) High risk Of the 904 patients who were eligible for
the study, 446 were randomised (49%).
Due to the number of patients declining
screening, there is an increased risk of in-
clusion bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors do not state whether the re-
searchers or personnel were blinded regard-
ing to which arm the participants were ran-
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domised.However, we can assume that par-
ticipants and physicians were not blinded
to treatment allocation due to the nature of
the intervention. Physicians who delivered
the intervention did not treat the usual care
arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome assessment was carried out
by an independent statistician who was
blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of 446 eligible participants who were ran-
domised, 434 (97%) were included in the
three-month follow-up evaluation
Selective reporting (reporting bias) Low risk The primary endpoint was use of appro-
priate antithrombotic therapy; other end-
points include TTR, patient’s readiness to
make choices, knowledge, decision con-
flict, acceptability of decision aid, satisfac-
tion, and adherence. Adherence and satis-
faction scales data are not explained in de-
tail. However, authors report the majority
of data from the protocol paper including
key primary and secondary outcomes
Other bias High risk There was an imbalance at baseline in an-
tithrombotic therapy between the interven-
tion and usual care groups which could
have influenced the patients’ ability to
make decisions regarding antithrombotic
therapy thereby affecting the outcomes. In
addition, a greater proportion of patients
were unwilling to consider changing treat-
ment at baseline in the decision aid group
compared to usual care (41% versus 36%)
andmore patients in the decision aid group
felt that their physician should make the
decision regarding antithrombotic therapy
than those in the usual care (52% versus
40%); both of which could have affected
patients’ decisional conflict. The study was
underpowered as the protocol paper sug-
gested that 814 participants were required
(N = 434 included)
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Methods Nested randomised controlled trial
Participants N randomised: intervention = 25 versus usual care = 28
Diagnosis of patients: mixed indication cohort
Demographics of the cohort:
Age: mean 63.71 (SD 16.04)
% female: not stated
% white: not stated
% education above primary level: not stated
Demographics of the AF patients: N = 14
Treatment group n = 5; usual care n = 9
Age: mean intervention = 73.6 (SD 11.1) versus mean usual care = 76 (SD 13.4)
% female: intervention = 4/5 (80%) versus usual care = 3/9 (33%)
% white: intervention = 3/5 (60%) versus usual care = 5/9 (55%)
% educated above primary school level: not available
Inclusion criteria: patients discharged to home on OAT, alert and orientated, able to
speak and understand English, and accessible via telephone
Exclusion criteria: patients discharged to a nursing home or rehabilitation facility, his-
tory of psychotic disorder or cognitive impairment
Interventions Type: enhanced educational intervention
Content: face-to-face warfarin education, printed materials, instruction, medical alert
bracelet. The intervention was based on Banduras social cognitive model and aimed to
improve self-efficacy. Four post-discharge phone calls assessing knowledge post-inter-
vention and correcting incorrect answers
Duration: not stated
Facilitator: pharmacist
Setting: hospital
Outcomes warfarin knowledge
self-efficacy
Country USA
Comparison usual care
Length follow-up 12 weeks
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomly assigned to the interven-
tion or usual care group after receiving patient ed-
ucation from the pharmacist. Authors do not de-
scribe the sequence generation
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Allocation concealment (selection bias) Unclear risk Of 66 patients whowere screened and offered par-
ticipation in the study, there were 53 included
in the original randomised sample (80% of those
screened), with a low risk of inclusion bias. Only
42/53 (79%) received the intervention or usual
care; 42/66 of eligible patients were therefore in-
cluded (64%)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors do not state whether the researchers
or personnel were blinded regarding to which arm
the participants were randomised. However, we
can assume that participants and physicians were
not blinded to treatment allocation due to the na-
ture of the intervention. The authors do not state
whether the personnel delivering the intervention
also treated the usual care arm
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Authors do not state whether the person scoring
the questionnaires was blinded to the treatment
allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk The final sample included42 (79%) of the original
53 patients that were randomised to the study. At-
trition was 36% and therefore designated as high
risk of bias
Selective reporting (reporting bias) Low risk The authors describe two outcomes in their
method section: (1) warfarin knowledge and (2)
self-efficacy. The authors report on both outcomes
in their results section. There was no published
protocol paper, thuswe cannot determine whether
those outcomes reported reflect those that were
included in the study
Other bias High risk Very small sample size (N = 42 in total)
Thomson 2007
Methods Three/two-armed open, randomised controlled efficacy trial
Participants N randomised: 69 decision aid versus 67 guidelines
Diagnosis of patients: all AF patients
Demographics of cohort:
Age: 73.1±6.7 decision aid versus 73.7±6.2 guidelines
% female: 43.4 decision aid versus 44.6 guidelines
% white: not stated
% education above primary level: not stated
Inclusion/exclusion criteria: Patients were recruited if theywere already taking warfarin
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or if they were considering taking warfarin for the first time. Patients were eligible if they
were aged 60 or over and had either chronic NVAF or PAF. Patients were excluded if they
had acute onset AF requiring cardioversion, previous stroke or TIA, contraindications
for warfarin, or cognitive impairment, or were taking warfarin for other indications,
non-English speaking, or at risk of cerebral bleed
Interventions Type: decision aid
Content: included individual risk and benefit presentation and a section to support
shared decision making
Two different decision aids:
1. Used explicit value elicitation employing the standard gamble method and Markov
decision analysis “explicit tool”
2. Included only risk/benefit presentation “implicit tool” (computerised decision aid).
The doctor was trained to use the computerised decision aid
Early in the trial, the observation study (running alongside the trial) found the first
decision aid to be difficult, so this arm was discontinued (gamble method) and the
paper describes the results of the second arm versus evidence-based paper guidelines.
The intervention arm included benefits and harms of warfarin treatment, advantages
and disadvantages, and personalised risk assessment (using the Framingham equation).
The presentation used graphical and numerical forms of presentation
Duration: mean 31 minutes long (range 16 to 41)
Facilitator: computerised tool
Setting: research clinic
Outcomes decision conflict
knowledge
state trait anxiety inventory
Degner’s decision making preference scale
Country Newcastle, UK
Comparison guideline-based consultation
Length follow-up three months
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised to either
computerised decision aid (intervention)
or evidence-based paper guidelines (con-
trol), using electronically-generated ran-
dom permuted blocks via a web-based ran-
domisation service provided by the Centre
for Health Services Research
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Allocation concealment (selection bias) High risk Of 483 patients who were eligible for the
study, 145 patients were eventually ran-
domised (30%). Thus there is a substantial
risk of inclusion bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors do not state whether the re-
searchers or personnel were blinded regard-
ing to which arm the participants were ran-
domised.However, we can assume that par-
ticipants and physicians were not blinded
to treatment allocation due to the nature of
the intervention. The authors do not state
whether those physicians delivering the in-
tervention also treated the usual care arm
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The authors do not state whether the per-
son scoring the questionnaires was blinded
to the treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Of the 69 patients allocated to the decision
aid tool, 16 (23%) did not receive the inter-
vention. Of the 67 patients allocated to the
guidelines group, 11 (16%) did not receive
the intervention. In total, 19% of patients
randomised did not receive the interven-
tion. More patients randomised to the de-
cision aid tool did not receive the interven-
tion although the overall attrition ratewas <
20%. Reasons included withdrawal of con-
sent, death, illness, surgery, alcoholism, and
inability to use the tool
Selective reporting (reporting bias) Unclear risk The primary outcome was decision con-
flict. Secondary outcomes were state and
trait anxiety, knowledge, and decisionmak-
ing preference. Decision conflict outcomes
were reported, but there was no tabulated
report of the scale breakdown. All of the
outcomes were reported, but mean scores
and numbers of patients per groupwere not
Other bias Unclear risk There was a difference at baseline between
the groups in the number of patients not
already receiving warfarin which may have
influenced patients’ ability/willingness to
make treatment decisions which may have
affected the primary outcome (decisional
conflict)
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Methods Prospective multicentre randomised controlled trial
Participants N randomised: 101 self-management versus 101 family doctor group
Diagnosis of patients: all NVAF patients
Demographics of cohort:
Age: 64.6±9.6 self-management versus 64.1±8.9 family doctor
% female: 28.6 self-management versus 38.6 family doctor
% white: not stated
% education above primary level: not stated
Inclusion/exclusion criteria:All patients for whom long-term anticoagulation was indi-
cated because of permanent non-valvular AF were included into the investigation. Exclu-
sion criteria were lack of suitability for INR self-management, participation in another
study, alcohol or other addiction, a mechanical heart valve replacement or anticoagulant
treatment already administered for another indication, and diseases such as AIDS or
carcinomas. Patients with visual impairment were also excluded
Interventions Content: educational session following the standards of the Working Group for the
Study of Patient Self-Management of Oral Anticoagulation, based on the intervention
session developed by Sawicki and colleagues. The programme consisted of three con-
secutive weekly teaching sessions for groups of three to six patients. Topics included
anticoagulation in general, INR self-monitoring, preventing bleeding, effects of diet and
other medication, reducing or increasing dose, problems that may be encountered with
operations, illness, exercise, pregnancy, etc
Duration: 60 to 90 minutes (based on Sawicki’s description)
Facilitator: not stated
Setting: not stated
Outcomes Primary endpoint:number of thromboembolic or hemorrhagic complications requiring
treatment
Secondary endpoints: the degree of handicap after stroke, the degree of severity of
haemorrhage, the proportion as well as cumulative time of the INR values in the indi-
vidual target range, INR variance, time course of complications, and the cost efficiency
of self-measurement compared to conventional procedures
Country Germany
Comparison family doctor group
Length follow-up Overall observation period (retrospective):
self-management 37.34±5.93 years
family doctor 40.25±6.07 years
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomisation list developed before be-
ginning of the study with SAS software
PROC PLAN procedure
Allocation concealment (selection bias) Unclear risk Authors do not report how many partici-
pants were eligible for the study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors do not state whether the re-
searcher or personnel were blinded regard-
ing to which arm the participants were ran-
domised.However, we can assume that par-
ticipants and physicians were not blinded
to treatment allocation due to the nature of
the intervention. The authors do not state
whether those physicians delivering the in-
tervention also treated the usual care arm
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The authors do not state whether the per-
son scoring the questionnaires was blinded
to the treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All of the 202 patients who were ran-
domised to the study were included in the
final analysis
Selective reporting (reporting bias) High risk The study was discontinued because the
number of cases was too small, and the
group comparisonwas confined to the eval-
uation of the number of INR values mea-
sured and the total period for which the pa-
tients remained outside, above, and below
the target range
Other bias High risk All patients had to be eligible for self-man-
agement of oral anticoagulation and there-
fore may not be representative of all AF pa-
tients requiring oral anticoagulation. The
mean age was 64 years which is fairly young
for an AF population. In addition, there
were only three primary outcome events
(two haemorrhages in the self-management
group and one thromboembolic event in
the family doctor group)
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Vormfelde 2014
Methods Cluster randomised controlled trial of 22 GP practices
Participants N randomised: intervention = 185 patients versus comparator = 134 patients
Diagnosis of patients: AF, thrombosis, pulmonary embolism, heart valve replacement,
unknown
Demographics for total cohort:
Age: 73±10 intervention versus 72±10 usual care
% female: 56% intervention versus 58% usual care
% white: not stated
% education above primary level: not stated
Demographics of the AF patients: N = 14
Treatment group n = 141 versus usual care n = 81
Age: intervention mean 74.5 (SD 8.0) versus usual care mean 72.9 (SD 9.4)
Female: intervention = 72 (45.6%) versus usual care = 38 (46.9%)
≥ 10 years education: intervention 32 (20.3%) versus usual care 28 (34.6%)
Inclusion/exclusion criteria: All patients taking OAT (with a range of indications) with
ability to consent to participation and adequate German language skills were included.
Exclusion criteria included residence in a nursing home and patients in cross coverage
Interventions Type: parallell randomised controlled trial
Content: Practice nurses delivered the educational intervention session consisting of a
20-minute video presentation, an eight-page brochure, and a corresponding question-
naire. The information was on 13 topics pertaining to oral anticoagulation with phen-
procoumon according to the internationally recognised model and recommendations.
Usual care included patients who were only given a brochure
Duration: one hour
Facilitator: practice nurse
Setting: general practice
Outcomes Primary outcome: number of correctly answered questions from the 13-item OAT ques-
tionnaire
Secondary outcomes: time spent in therapeutic range, subjective feelings of safety and
complications related to OAT
Country Germany
Comparison patients who were only given the brochure
Length follow-up six months
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The first 22 GPs that agreed to partici-
pate were included. The Institute for Med-
ical Statistics randomised these 22 practices
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Vormfelde 2014 (Continued)
into two equal-sized trial groups (interven-
tion versus control) by random permuta-
tion
Allocation concealment (selection bias) High risk Of the 85 general medical practices con-
tacted, 22 general medical practices agreed
to participate (26%). There is risk of bias
from participation of more highly moti-
vated and better educated individuals than
average, who knew they were being tested
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors do not state whether the re-
searchers or personnel were blinded regard-
ing to which arm the participants were
randomised. However, we can assume that
participants and practice nurses were not
blinded to treatment allocation due to the
nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The authors do not state whether their data
analysis was blinded regarding to which
group the patients were randomised
Incomplete outcome data (attrition bias)
All outcomes
High risk Of the 979 anticoagulated patients who
were identified in the 22 practices, 319
completed the trial (33%). During follow-
up, for the intervention arm (n = 194), nine
(5%) did not complete the trial as eight
moved away and one died. For the control
arm (n = 151), 17 (11%) patients did not
complete the trial as six moved away, three
died, and eight chose to drop out. INR
analysis was possible in 157/194 (81%) pa-
tients in the intervention group and91/151
(60%) in the control arm; overall attrition
was greater than 20% and more patients in
the control group did not have INR data at
follow-up available for the analyses
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported.
Other bias High risk Improvement in knowledge was dependent
on the practice where the patient education
was delivered which was probably due to
differences in the discussion with the nurse
after the video presentation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al-Meshal 2013 No breakdown of patient group
Armstrong 2011 Not an RCT
Bajorek 2005 Not an RCT, no control group
Baker 1991 Wrong patient group, no AF
Barcellona 2006 No unpublished AF data provided on request
Batty 2001 Does not measure any of the required outcomes
Bereznicki 2013 No separate control group, patients acted as their own historical control
Blaise 2009 Not an RCT, retrospective study
Bloomfield 2011 Meta-analysis, not an RCT
Bump 1977 No AF patients
Burns 2009 Not an RCT, review paper
Castelino 2010 Not an RCT
Chan 2006 No unpublished AF data provided on request
Christensen 2011 Limited education, specific to self-testing
Claes 2005 No AF patients
Claes 2006 No AF patients
Corbella 2009 Not an RCT
Cordasco 2009 No AF patients
Cromheecke 2000 No AF patients
Cromheecke 2001 No AF patients
Davis 2005 Not an RCT, survey
Dolor 2010 No education other than instruction to self-test
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(Continued)
Duran-Parrondo 2011 Trial is not randomised
Field 2010 Training is for staff not patients
Fitzmaurice 1996 Not a patient intervention
Fitzmaurice 2000 Did not include an educational or behavioural intervention
Fitzmaurice 2005 No AF patients
Fraenkel 2011 Not compared to usual care, not an RCT
Gardiner 2006 No unpublished AF data provided on request
Gouin-Thibault 2010 Intervention for staff not patients
Grunau 2011 Patients were educated on self-monitoring only
Hasan 2011 Not an RCT
Heidbuchel 2015 Not an RCT, review article
Holbrook 2007 No AF patients
Jackson 2004 Does not measure any of the required outcomes
Jank 2009 No unpublished AF data provided on request
Khan 2004 Randomisation procedure did not meet inclusion criteria
Krause 2010 Systematic review not an RCT
Lakshmi 2013 No unpublished AF data provided on request
Landefeld 1992 No AF patients
Leger 2004 Not an RCT, wrong patient group
Machtinger 2007 No unpublished AF data provided on request
Matchar 2005 No education or behaviour change within the intervention
Matchar 2010 Self-monitoring only, no educational or behavioural intervention
Mazor 2007 No AF patients
McCahon 2011 No breakdown of patient group
63Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Megden 1999 Not an RCT
Menendez-Jandula 2005 No unpublished AF data provided on request
Moore 2013 No breakdown of patient group
Morin 2015 Not an RCT, research model
Moss 2014 No unpublished AF data provided on request
Nedaz 2002 Not an RCT, this paper is a commentary
Nilsson 2011 Abstract only, no mention of AF patients
O’Sullivan 2016 Does not include any of the primary or secondary outcomes
Peng 2014 Does not include any of the primary or secondary outcomes
Pernod 2008 No AF patients
Polzien 2007 Not an RCT, commentary
PRISM Study group 2003 Does not include any of the primary or secondary outcomes
Qvist 2016 Not an RCT, no comparison group
Reverdin 2011 Not an RCT
Ryan 2009 No unpublished AF data provided on request
Saokaew 2010 Systematic review and meta-analysis, not an RCT
Satger 2009 Not an RCT, review article
Sawicki 1999 No unpublished AF data provided on request
Sawicki 2003 Not an RCT, no comparison group
Siebenhofer 2007 No unpublished AF data provided on request
Stafford 2011 Not a randomised trial
Stone 1989 No unpublished AF data provided on request
Sunderji 2005 Education only relates to self-monitoring
Suriano 2014 No breakdown of patient group
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(Continued)
Taylor 1997 Not an RCT
Trivalle 2010 Education of staff not patients
Tuiskula 2011 Not an RCT
Turc-Dessertine 2005 Not an RCT, survey. No intervention or control group
Vadher 1996 No breakdown of patient group
Vadher 1997 No breakdown of patient group
Verret 2012 No breakdown of patient group
Waterman 2001 No AF patients, no comparison group
Waterman 2001 b No patient intervention
Watzke 2000 No unpublished AF data provided on request
Winans 2010 Not an RCT
Witt 2005 Not an RCT, retrospective, observational cohort study
Woodend 2005 Not an RCT (commentary)
Wurster 2006 Not an RCT
Yildirim 2015 No unpublished AF data provided on request
Characteristics of ongoing studies [ordered by study ID]
Siebenhofer 2012
Trial name or title Primary Care Management for Optimized Antithrombotic Treatment [PICANT]
Methods Cluster randomised controlled trial
Participants Patients with an indication for oral anticoagulation
Interventions Patient information leaflet and a video developed by Vormfelde 2014, treatment monitoring via the Coagu-
lation Monitoring List, and encouragement to participate in a self-management course where they will learn
how to carry out self-testing and self-dosing
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Siebenhofer 2012 (Continued)
Outcomes Primary outcome: combined endpoint of all thromboembolic events requiring hospitalisation and all major
bleeding complications
Secondary outcomes: mortality, hospitalisation, stroke, major bleeding and thromboembolic complications,
severe treatment interactions, number of adverse events, quality of anticoagulation, health-related quality of
life, and costs
Starting date July 2012
Contact information siebenhofer@allgemeinmedizin.uni-frankfurt.de
Notes
ACCP: American College of Clinical Pharmacy
AF: atrial fibrillation
ECG: Electrocardiography
GP: general practitioner
INR: international normalised ratio
NVAF: nonvalvular atrial fibrillation
OAT: oral anticoagulation therapy
PAF: paroxysmal atrial fibrillation
SPAF Stroke Prevention in Atrial Fibrillation Study
TIA: transient ischemic attack
TTR: time in therapeutic range
VTE: venous thromboembolism
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D A T A A N D A N A L Y S E S
Comparison 1. Self-monitoring plus education versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time in therapeutic INR range 2 69 Mean Difference (IV, Fixed, 95% CI) 6.31 [-5.63, 18.25]
Comparison 2. Education versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HADS anxiety 2 587 Mean Difference (IV, Fixed, 95% CI) -0.62 [-1.21, -0.04]
2 HADS depression 2 587 Mean Difference (IV, Fixed, 95% CI) -0.74 [-1.34, -0.14]
Comparison 3. Decision-aid versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Decision conflict 2 721 Mean Difference (IV, Random, 95% CI) -0.10 [-0.17, -0.02]
67Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Self-monitoring plus education versus usual care, Outcome 1 Time in
therapeutic INR range.
Review: Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
Comparison: 1 Self-monitoring plus education versus usual care
Outcome: 1 Time in therapeutic INR range
Study or subgroup Intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Christensen 2007 11 77.3 (11.59) 9 67.96 (23.52) 50.3 % 9.34 [ -7.48, 26.16 ]
Gadisseur 2003 6 70.32 (18.73) 43 67.08 (26.43) 49.7 % 3.24 [ -13.70, 20.18 ]
Total (95% CI) 17 52 100.0 % 6.31 [ -5.63, 18.25 ]
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours intervention Favours usual care
Analysis 2.1. Comparison 2 Education versus usual care, Outcome 1 HADS anxiety.
Review: Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
Comparison: 2 Education versus usual care
Outcome: 1 HADS anxiety
Study or subgroup Intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Clarkesmith 2013 17 9.12 (4.15) 36 9.97 (4.03) 6.1 % -0.85 [ -3.22, 1.52 ]
Hendriks 2013 286 4.85 (3.41) 248 5.46 (3.68) 93.9 % -0.61 [ -1.21, -0.01 ]
Total (95% CI) 303 284 100.0 % -0.62 [ -1.21, -0.04 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours intervention Favours usual care
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Analysis 2.2. Comparison 2 Education versus usual care, Outcome 2 HADS depression.
Review: Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
Comparison: 2 Education versus usual care
Outcome: 2 HADS depression
Study or subgroup Intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Clarkesmith 2013 17 7.18 (3.13) 36 8.11 (3.06) 11.2 % -0.93 [ -2.72, 0.86 ]
Hendriks 2013 286 3.84 (3.51) 248 4.56 (3.95) 88.8 % -0.72 [ -1.36, -0.08 ]
Total (95% CI) 303 284 100.0 % -0.74 [ -1.34, -0.14 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.015)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours intervention Favours usual care
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Analysis 3.1. Comparison 3 Decision-aid versus usual care, Outcome 1 Decision conflict.
Review: Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
Comparison: 3 Decision-aid versus usual care
Outcome: 1 Decision conflict
Study or subgroup Intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Man-Son-Hing 1999 139 1.65 (0.45) 148 1.74 (0.54) 40.2 % -0.09 [ -0.20, 0.02 ]
McAlister 2005 219 1.6 (0.5) 215 1.7 (0.5) 59.8 % -0.10 [ -0.19, -0.01 ]
Total (95% CI) 358 363 100.0 % -0.10 [ -0.17, -0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0097)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours intervention Favours usual care
A P P E N D I C E S
Appendix 1. Search strategy
The Cochrane Library
#1 MeSH descriptor patient education as topic this term only
#2 MeSH descriptor attitude to health explode all trees
#3 MeSH descriptor patient participation this term only
#4 MeSH descriptor behavior therapy this term only
#5 MeSH descriptor cognitive therapy this term only
#6 MeSH descriptor counseling explode all trees
#7 MeSH descriptor motivation this term only
#8 MeSH descriptor goals this term only
#9 MeSH descriptor Biofeedback (Psychology) this term only
#10 MeSH descriptor decision support techniques this term only
#11 MeSH descriptor Communications Media explode all trees
#12 education in All Text
#13 (training in All Text or train in All Text)
#14 (teaching in All Text or teach in All Text)
#15 (behaviour* in All Text or behavior* in All Text)
#16 “patient knowledge” in All Text
#17 counsel* in All Text
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#18 (cognitiv* in All Text near/3 therapy in All Text)
#19 (cognitiv* in All Text near/3 intervention* in All Text)
#20 motivation* in All Text
#21 contingency next management in All Text
#22 (biofeedback in All Text or bio-feedback in All Text)
#23 (goal in All Text or goals in All Text)
#24 (decision* in All Text near/3 aid* in All Text)
#25 pamphlet* in All Text
#26 booklet* in All Text
#27 video* in All Text
#28 decision next aid* in All Text
#29 “patient participation” in All Text
#30 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10)
#31 (#11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20)
#32 (#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29)
#33 (#30 or #31 or #32)
#34 MeSH descriptor warfarin this term only
#35 MeSH descriptor Coumarins explode all trees
#36 MeSH descriptor anticoagulants this term only
#37 MeSH descriptor vitamin k explode all trees with qualifiers: AI
#38 oral next anticoagula* in All Text
#39 Oral next anti-coagula* in All Text
#40 (“vitamin K” in All Text and (antagonist* in All Text or inhibitor* in All Text) )
#41 “antivitamin K” in All Text
#42 “anti-vitamin K” in All Text
#43 warfarin in All Text
#44 acenocoumarol in All Text
#45 sintrom in All Text
#46 sinthrome in All Text
#47 jantoven in All Text
#48 marevan in All Text
#49 coumadin* in All Text
#50 waran in All Text
#51 phenprocoumon in All Text
#52 nicoumalone in All Text
#53 VKA in All Text
#54 coumarin* in All Text
#55 dicoumarol in All Text
#56 dicumarol in All Text
#57 (#34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43)
#58 (#44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56)
#59 (#57 or #58)
#60 (#33 and #59)
MEDLINE on Ovid
1. Warfarin/
2. acenocoumarol/
3. Coumarins/
4. Phenindione/
5. Dicumarol/
6. Anticoagulants/
7. oral anticoagula$.tw.
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8. exp Vitamin K/ai [Antagonists & Inhibitors]
9. warfarin.tw.
10. acenocoumarol.tw.
11. sintrom.tw.
12. sinthrome.tw.
13. jantoven.tw.
14. marevan.tw.
15. coumadin$.tw.
16. waran.tw.
17. Phenprocoumon/
18. nicoumalone.tw.
19. (vitamin k adj3 antagonist$).tw.
20. vitamin k inhibitor$.tw.
21. oral anticoagula$.tw.
22. oral anti-coagula$.tw.
23. vka.tw.
24. antivitamin k.tw.
25. anti-vitamin k.tw.
26. or/1-25
27. Patient Education as Topic/
28. exp Attitude to Health/
29. Patient Participation/
30. ((educat$ or train$ or teach$) adj3 (program$ or intervention$)).tw.
31. (patient$ adj3 (train$ or teach$ or educat$ or inform$)).tw.
32. patient knowledge.tw.
33. Behavior Therapy/
34. Cognitive Therapy/
35. exp counseling/
36. (behavi$ adj3 (therap$ or manage$ or modif$ or chang$ or intervention$)).tw.
37. (cogniti$ adj3 (therap$ or intervention$)).tw.
38. counsel$.tw.
39. Motivation/
40. motivational interview$.tw.
41. contingency management.tw.
42. biofeedback.tw.
43. bio-feedback.tw.
44. goals/
45. (goal$ adj3 set$).tw.
46. decision support techniques/
47. decision$ aid$.tw.
48. exp communications media/
49. pamphlet$.tw.
50. booklet$.tw.
51. video$.tw.
52. or/27-51
53. 26 and 52
54. randomized controlled trial.pt.
55. controlled clinical trial.pt.
56. randomized.ab.
57. placebo.ab.
58. clinical trials as topic.sh.
59. randomly.ab.
60. trial.ti.
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61. 54 or 55 or 56 or 57 or 58 or 59 or 60
62. exp animals/ not humans.sh.
63. 61 not 62
64. 53 and 63
EMBASE Ovid
RCT filter as recommended in the Cochrane Handbook (Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In:
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009).
The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.) applied.
1. phenindione/
2. antivitamin K/
3. exp coumarin anticoagulant/
4. anticoagulant agent/
5. warfarin.tw.
6. acenocoumarol.tw.
7. sintrom.tw.
8. sinthrome.tw.
9. jantoven.tw.
10. marevan.tw.
11. coumadin$.tw.
12. waran.tw.
13. nicoumalone.tw.
14. (vitamin k adj3 antagonist$).tw.
15. vitamin k inhibitor$.tw.
16. oral anticoagula$.tw.
17. oral anti-coagula$.tw.
18. vka*.tw.
19. antivitamin k.tw.
20. anti-vitamin k.tw.
21. coumarin$.tw.
22. vitamin K group/po [Oral Drug Administration]
23. or/1-22
24. patient education/
25. attitude to health/
26. patient participation/
27. ((educat$ or train$ or teach$) adj3 (program$ or intervention$)).tw.
28. (patient$ adj3 (train$ or teach$ or educat$ or inform$)).tw.
29. patient knowledge.tw.
30. behavior therapy/
31. cognitive therapy/
32. exp counseling/
33. (behavi$ adj3 (therap$ or manage$ or modif$ or chang$ or intervention$)).tw.
34. (cogniti$ adj3 (therap$ or intervention$)).tw.
35. counsel$.tw.
36. motivation/
37. motivational interview$.tw.
38. contingency management.tw.
39. biofeedback.tw.
40. bio-feedback.tw.
41. (goal$ adj3 set$).tw.
42. decision support system/
43. decision$ aid$.tw.
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44. (decision$ adj3 support).tw.
45. mass medium/
46. pamphlet$.tw.
47. booklet$.tw.
48. video$.tw.
49. or/24-48
50. random$.tw.
51. factorial$.tw.
52. crossover$.tw.
53. cross over$.tw.
54. cross-over$.tw.
55. placebo$.tw.
56. (doubl$ adj blind$).tw.
57. (singl$ adj blind$).tw.
58. assign$.tw.
59. allocat$.tw.
60. volunteer$.tw.
61. crossover procedure/
62. double blind procedure/
63. randomized controlled trial/
64. single blind procedure/
65. or/50-64
66. (animal/ or nonhuman/) not human/
67. 65 not 66
68. 23 and 49 and 67
PsycINFO
1. anticoagulant drugs/
2. warfarin.tw.
3. acenocoumarol.tw.
4. coumadin$.tw.
5. waran.tw.
6. nicoumalone.tw.
7. (vitamin k adj3 antagonist$).tw.
8. oral anticoagula$.tw.
9. vka*.tw.
10. coumarin$.tw.
11. or/1-10
12. client education/
13. client participation/
14. behavior therapy/
15. cognitive therapy/
16. exp counseling/
17. motivation/
18. exp goals/
19. biofeedback/
20. decision making/
21. exp communications media/
22. ((educat$ or train$ or teach$) adj3 (program$ or intervention$)).tw.
23. (patient$ adj3 (train$ or teach$ or educat$ or inform$)).tw.
24. patient knowledge.tw.
25. health knowledge/
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26. (behavi$ adj3 (therap$ or manage$ or modif$ or chang$ or intervention$)).tw.
27. (cogniti$ adj3 (therap$ or intervention$)).tw.
28. health attitudes/
29. counsel$.tw.
30. motivational interview$.tw.
31. contingency management.tw.
32. biofeedback.tw.
33. bio-feedback.tw.
34. (goal$ adj3 set$).tw.
35. decision$ aid$.tw.
36. (decision$ adj3 support).tw.
37. pamphlet$.tw.
38. booklet$.tw.
39. video$.tw.
40. or/12-39
41. 11 and 40
42. random$.tw.
43. factorial$.tw.
44. crossover$.tw.
45. cross-over$.tw.
46. placebo$.tw.
47. (doubl$ adj blind$).tw.
48. (singl$ adj blind$).tw.
49. assign$.tw.
50. allocat$.tw.
51. volunteer$.tw.
52. control*.tw.
53. “2000”.md.
54. or/42-53
55. 41 and 54
CINAHL
as run on 9 August 2012:
S72 S52 and S71
S71 S53 or S54 or S55 or S56 or S57 or S58 or S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69 Limiters
- Published Date from: 20100501-20120931
S70 S53 or S54 or S55 or S56 or S57 or S58 or S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69
S69 cross-over*
S68 crossover*
S67 volunteer*
S66 (MH “Crossover Design”)
S65 allocat*
S64 control*
S63 assign*
S62 placebo*
S61 (MH “Placebos”)
S60 random*
S59 (doubl* N1 mask*)
S58 (singl* N1 mask*)
S57 (doubl* N1 blind*)
S56 (singl* N1 blind)
S55 (clinic* N1 trial?)
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S54 PT clinical trial
S53 (MH “Clinical Trials”)
S52 S25 and S51
S51 S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43
or S44 or S45 or S46 or S47 or S48 or S49 or S50
S50 video*
S49 booklet*
S48 pamphlet*
S47 (MH “Communications Media”)
S46 (decision* aid*)
S45 (MH “Decision Support Techniques”)
S44 (goal* N3 set*)
S43 (MH “Goals and Objectives”)
S42 bio-feedback
S41 biofeedback
S40 contingency management
S39 motivational interview*
S38 (MH “Motivation”)
S37 counsel*
S36 (cogniti* N3 (therap* or intervention*))
S35 (behavi* N3 (therap* or manage* or modif* or chang* or intervention*))
S34 (MH “Counseling”)
S33 (MH “Cognitive Therapy”)
S32 (MH “Behavior Therapy”)
S31 patient knowledge
S30 (patient* N3 (train* or teach* or educat* or inform*))
S29 ((educat* or train* or teach*) N3 (program* or intervention*))
S28 (MH “Consumer Participation”)
S27 (MH “Attitude to Health”)
S26 (MH “Patient Education”)
S25 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20
or S21 or S22 or S23 or S24
S24 anti-vitamin k
S23 antivitamin k
S22 vka*
S21 oral anti-coagula*
S20 oral anticoagula*
S19 vitamin k inhibitor*
S18 (vitamin k N3 antagonist*)
S17 nicoumalone
S16 “Phenprocoumon”
S15 waran
S14 coumadin*
S13 marevan
S12 jantoven
S11 sinthrome
S10 sintrom
S9 warfarin
S8 (MH “Vitamin K”)
S7 oral anticoagula*
S6 (MH “Anticoagulants”)
S5 “Dicumarol”
S4 “Phenindione”
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S3 “Coumarins”
S2 “acenocoumarol”
S1 (MH “Warfarin”)
as run on 21 June 2010:
S76 S57 and S75
S75 S58 or S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69 or S70 or S71 or S72 or S73 or S74
S74 TX cross-over*
S73 TX crossover*
S72 TX volunteer*
S71 (MH “Crossover Design”)
S70 TX allocat*
S69 TX control*
S68 TX assign*
S67 TX placebo*
S66 (MH “Placebos”)
S65 TX random*
S64 TX (doubl* N1 mask*)
S63 TX (singl* N1 mask*)
S62 TX (doubl* N1 blind*)
S61 TX (singl* N1 blind*)
S60 TX (clinic* N1 trial?)
S59 PT clinical trial
S58 (MH “Clinical Trials+”)
S57 S17 and S56
S56 S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35
or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49 or S50 or S51 or S52 or S53 or
S54 or S55
S55 (TI video*) or (AB video*)
S54 (TI booklet*) or (AB booklet*)
S53 (TI pamphlet*) or (AB pamphlet*)
S52 (MH “Communications Media+”)
S51 (TI decision* N3 support) or (AB decision* N3 support)
S50 (TI “decision* aid*”) or (AB “decision* aid*”)
S49 (MH “Decision Support Techniques+”)
S48 (TI goal* N3 set*) or (AB goal* N3 set*)
S47 (TI bio-feedback) or (AB bio-feedback)
S46 (TI biofeedback) or (AB biofeedback)
S45 (TI “contingency management”) or (AB “contingency management”)
S44 (TI “motivational interview*”) or (AB “motivational interview*”)
S43 (MH “Motivation+”)
S42 (TI counsel*) or (AB counsel*)
S41 (TI cogniti* N3 intervention*) or (AB cogniti* N3 intervention*)
S40 (TI cogniti* N3 therap*) or (AB cogniti* N3 therap*)
S39 (TI behavi* N3 intervention*) or (AB behavi* N3 intervention*)
S38 (TI behavi* N3 chang*) or (AB behavi* N3 chang*)
S37 (TI behavi* N3 modif*) or (AB behavi* N3 modif*)
S36 (TI behavi* N3 manage*) or (AB behavi* N3 manage*)
S35 (TI behavi* N3 therap*) or (AB behavi* N3 therap*)
S34 (MH “Counseling+”)
S33 (MH “Cognitive Therapy”)
S32 (MH “Behavior Therapy”)
S31 (TI “patient knowledge”) or (AB “patient knowledge”)
S30 (TI patient* N3 inform*) or (AB patient* N3 inform*)
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S29 (TI patient* N3 educat*) or (AB patient* N3 educat*)
S28 (TI patient* N3 teach*) or (AB patient* N3 teach*)
S27 (TI patient* N3 train*) or (AB patient* N3 train*)
S26 (TI teach* N3 intervention*) or (AB teach* N3 intervention*)
S25 (TI teach* N3 program*) or (AB teach* N3 program*)
S24 (TI train* N3 intervention*) or (AB train* N3 intervention*)
S23 (TI train* N3 program*) or (AB train* N3 program*)
S22 (TI educat* N3 intervention*) or (AB educat* N3 intervention*)
S21 (TI educat* N3 program*) or (AB educat* N3 program*)
S20 (MH “Consumer Participation”)
S19 (MH “Attitude to Health”)
S18 (MH “Patient Education”)
S17 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16
S16 (TI dicumarol) or (AB dicumarol)
S15 (TI dicoumarol) or (AB dicoumarol)
S14 (TI coumarin*) or (AB coumarin*)
S13 (TI VKA*) or (AB VKA*)
S12 (TI phenprocoumon) or (AB phenprocoumon)
S11 (TI coumadin*) or (AB coumadin*)
S10 (TI sintrom) or (AB sintrom)
S9 (TI acenocoumarol) or (AB acenocoumarol)
S8 (TI warfarin) or (AB warfarin)
S7 (TI “antivitamin K”) or (AB “antivitamin K”)
S6 (TI “vitamin K” N2 inhibitor*) or (AB “vitamin K” N2 inhibitor*)
S5 (TI “vitamin K” N2 antagonist*) or (AB “vitamin K” N2 antagonist*)
S4 (TI oral N2 anti-coagula*) or (AB oral N2 anti-coagula*)
S3 (TI oral N2 anticoagula*) or (AB oral N2 anticoagula*)
S2 (MH “Warfarin”)
S1 (MH “Anticoagulants”)
WH A T ’ S N E W
Last assessed as up-to-date: 8 February 2016.
Date Event Description
1 November 2016 New search has been performed This is an update of the original search and review pub-
lished in 2013. This update has added an additional 10
articles based on 3 studies (Clarkesmith 2013;Hendriks
2013; Vormfelde 2014). The additional studies were all
educational interventions. Data from two of these trials
(Hendriks 2013; Clarkesmith 2013) on anxiety and de-
pression were pooled (Analysis 2.1; Analysis 2.2). Data
from the additional trials were also included (but not
pooled) for time in therapeutic range, education, qual-
ity of life, beliefs about medication, and cost effective-
ness. A summary of findings table has been added to the
update (Summary of findings for themain comparison)
.
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(Continued)
1 November 2016 New citation required and conclusions have changed Three additional trials reported in this update compared
with 2013 review. Additional data contributed to novel
synthesis of analysis of effects on anxiety and depression
C O N T R I B U T I O N S O F A U T H O R S
Data collection, paper searches, screening and appraisal, and data extraction were conducted by Miss Khaing and Drs Clarkesmith and
Lane. Dr Clarkesmith wrote the initial draft of the Introduction and Methods of the review paper, which was edited by Dr Lane. Drs
Clarkesmith and Lane performed the data analysis together and drafted the Results and Discussion sections. Both Dr Clarkesmith and
Dr Lane revised and commented on subsequent drafts. Professor Pattison contributed to the interpretation of the analyses and provided
critical revision of drafts of the review.
D E C L A R A T I O N S O F I N T E R E S T
Dr Clarkesmith completed a PhD studentship that was funded by an Investigator-Initiated Educational Grant from Bayer Healthcare
and Aston University when the original review was conducted, but currently works as a post-doctoral researcher with no conflicts
of interest. Miss Khaing reports no conflicts of interest. Dr Lane was the principal grant holder for the ’TRial of an Educational
intervention on patients’ knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with
warfarin’ (TREAT). Dr Clarkesmith was the primary investigator for TREAT. Dr Lane and Professor Pattison were the educational
supervisors of Dr Clarkesmith for the TREAT study. This review is not funded by Bayer Healthcare.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• University of Birmingham Centre for Cardiovascular Sciences, City Hospital, UK.
• Aston University, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. Contributions of the authors
The contributions of authors has changed from the original protocol (see contributions of authors section).
2. Decision conflict as a secondary outcome
Decision conflict was included as a secondary outcome in the final analysis. Whilst not specified as an outcome of interest in the original
protocol, it was highlighted as a common secondary outcome measure in three of the studies included in the final review. For this
reason, the authors decided to include these data within the results.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗International Normalized Ratio [standards]; ∗Patient Education as Topic; Administration, Oral; Anticoagulants [∗administration &
dosage; adverse effects]; Atrial Fibrillation [blood; ∗complications]; Chronic Disease; Decision Support Techniques; Drug Monitoring
[∗methods; standards]; Medication Adherence; Randomized Controlled Trials as Topic; Self Care [methods]; Stroke [blood; etiology;
∗prevention & control]
MeSH check words
Aged; Humans; Middle Aged
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